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Abstract: Biomarker-guided treatment is a rapidly developing area of medicine, where treatment 
choice is personalised according to one or more of an individual’s biomarker measurements. A 
number of biomarker-guided trial designs have been proposed in the past decade, including both 
adaptive and non-adaptive trial designs which test the effectiveness of a biomarker-guided 
approach to treatment with the aim of improving patient health. A better understanding of them is 
needed as challenges occur both in terms of trial design and analysis. We have undertaken a 
comprehensive literature review based on an in-depth search strategy with a view to providing the 
research community with clarity in definition, methodology and terminology of the various 
biomarker-guided trial designs (both adaptive and non-adaptive designs) from a total of  
211 included papers. In the present paper, we focus on non-adaptive biomarker-guided trial designs 
for which we have identified five distinct main types mentioned in 100 papers. We have graphically 
displayed each non-adaptive trial design and provided an in-depth overview of their key 
characteristics. Substantial variability has been observed in terms of how trial designs are described 
and particularly in the terminology used by different authors. Our comprehensive review provides 
guidance for those designing biomarker-guided trials. 
Keywords: biomarker-guided trial design; clinical research design; phase II; phase III; personalized 
medicine; predictive biomarker; prognostic biomarker; non-adaptive trial designs; clinical trials 
methodology; sample size 
 
 
1. Introduction 
The rapidly developing field of ‘personalized medicine’ [1], also known as ‘individualized 
medicine’, ‘stratified medicine’, or ‘precision medicine’ is allowing scientists to treat patients by 
providing them with a specific regimen according to their individual demographic, genomic or 
biological characteristics. The latter two aforementioned characteristics are collectively known as 
biomarkers [2]. The terms ‘personalized medicine’ and ‘individualized medicine’ often create 
confusion in literature, as in reality, the objective of this approach is to identify demographic- or 
biomarker-defined subgroups. Thus, as it still remains a population and not an individualized 
approach, the terms ‘stratified’ or ‘precision’ medicine are often considered to be more accurate. The 
National Institutes of Health Biomarkers Definitions Working Group [3] defined a biomarker to be 
“a characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” [1,4-7]. 
  
Biomarkers related to clinical outcome which are measured before treatment commences can be 
classified as either prognostic or predictive biomarkers. Prognostic biomarkers provide information 
regarding the likely progression of a disease without taking into account any specific treatment, 
whilst predictive biomarkers provide information about the patient’s outcome given a certain 
treatment, i.e., their likely response to the treatment [4,7-34]. Prior to utilizing a patient’s biomarker 
information in clinical practice, it is necessary that they have been robustly tested in terms of 
analytical validity (the results of testing a specific biomarker or biomarkers can be trusted), clinical 
validity (the results obtained from the test correlates with important clinical information) and clinical 
utility (the test will be useful in ameliorating patients’ health) [9,13,19,25].  
A number of phase II and phase III trial designs have been proposed for testing the clinical utility 
of prognostic biomarkers. Due to the large amount of literature in this field, we have split our review 
into two broad categories, i.e., the biomarker-guided non-adaptive trial designs which are presented 
in the current study and the biomarker-guided adaptive trial designs. The latter are extensively 
discussed in our published paper “Biomarker-Guided Adaptive Trial Designs in Phase II and Phase 
III: a Methodological Review”, Antoniou et al., 2016 [35].  
In this review we aim to communicate the different non-adaptive biomarker-guided trial 
designs, which can be either randomized or non-randomized designs (e.g., single-arm designs), 
proposed in the literature so far and to report on the potential advantages and weaknesses of each. 
Although not included in the paper by Antoniou et al., 2016 [35] which describes and discusses 
adaptive designs, some designs discussed in the current paper, although not adaptive in the 
traditional sense, they own an adaptive element. 
2. Methods and Findings 
We undertook a search of the MEDLINE (Ovid) database, restricted to published papers in the 
English language within the previous ten years aiming to identify articles which describe and discuss 
biomarker-guided trial designs. Traditional trial designs, i.e., designs which do not incorporate 
biomarkers aiming to aid in making treatment decisions (we will refer to as ‘traditional’ trial designs) 
are part of our literature review search strategy in order to help us identify and distinguish any 
potential reference to biomarker-guided designs, as the finding of the appropriate keywords in 
Medline database for biomarker-guided designs was challenging. Furthermore, the restriction of 
published papers within the past decade was made not only because of the large amount of literature 
in this field, but also for the identification of the most recent trial designs. Two separate strategies as 
illustrated in Figure 1 were used to identify relevant articles, and the keywords utilized in the search 
are presented in S1 Keywords. Our initial search resulted in 9412 and 5024 relevant titles for 
biomarker-guided clinical trial designs and traditional trial designs, respectively. From the 9412 
papers, 104 articles were included based on their title and abstract. From the 5024 papers, 40 articles 
were included based on their title and abstract and after removing inaccessible articles or those 
already identified in the search for biomarker-guided trial designs. An additional 67 eligible papers 
were identified from searching both the reference list of included articles and the internet (the internet 
searches were performed using the same keywords as those for the Ovid strategy), making a total of 
211 included papers. Of these 211 included papers, biomarker-guided non-adaptive trial designs 
were referred to in 100 papers; 107 papers for biomarker-guided adaptive trial designs were reviewed 
in our published paper Antoniou et al., 2016 [35]. In the total number of 211 papers, some papers are 
referred to both adaptive and non-adaptive designs. Articles from references and internet searches 
which did not provide further information on each broad category of biomarker-guided designs were 
not included. Cited books, web pages for actual trials and papers published before 2005 are also not 
included in these numbers. For each included paper, the following details were extracted: definition 
of the trial design(s) referred to in the paper, how patients were screened and/or randomized based 
on their biomarker status, treatment groups randomized to, as well as other key information relating 
to the trial design and methodology, including advantages and limitations. Where reference was 
made in the included papers to an actual trial which had adopted a particular biomarker-guided non-
adaptive trial design, the clinical field with which the trial was associated was also recorded. 
  
However, a review of all implementations of the different trial designs in practice is beyond the scope 
of this paper; however, and is an area for potential future work. Therefore, it is important to highlight 
that even where no evidence of the implementation of a particular design was found in the papers 
included in our review, the design may well be currently in use in ongoing trials. 
 
Figure 1. Flow diagram of the review process. From our search strategy a total number of 211 papers 
have been identified giving information regarding not only the biomarker-guided designs but also 
general information about personalized medicine and biomarkers. Before arriving at 211 papers, 
books, web pages for actual trials and papers published before 2005 were excluded. The 211 papers 
are split into two overlapping sets of 100 and 107 papers. The total of 207 is less than 211 due to 
overlap of papers, and also due to the fact that some articles referring to general information about 
personalized medicine and biomarkers and articles which do not provide further information on each 
broad of biomarker-guided designs were excluded. The 107 papers for biomarker-guided adaptive 
trial designs were reviewed in our published paper Antoniou et al. (2016) [35]. 
In our review, we identified five main biomarker-guided non-adaptive trial designs namely:  
(i) single-arm designs; (ii) enrichment designs; (iii) randomize-all designs; (iv) biomarker-strategy 
designs and (v) other designs. Within each main design several subtypes and extensions were also 
identified. Graphical representations of the main designs and subtypes are given in Figures 2-16. 
Graphical representations of the extensions are given in Figures S1-S4 included in File S1-S4. The 
characteristics and methodology of the main design types and subtypes are discussed below and are 
  
summarized in Table 1, whilst information on the extensions are discussed in File S1-S4. Furthermore, 
sample size formulae for each biomarker-guided design are provided in Table 2. 
  
Table 1. Types of Biomarker guided non-adaptive designs proposed within the last ten years. 
Types of Biomarker-Guided Non-Adaptive 
Trial Designs 
Utility Advantages Limitations 
Single arm designs (7 papers) [30,36-41] 
(see Figure 2) 
Useful for initial identification and/or 
validation of a biomarker. 
(A1) Considered as a simple statistical design as 
there is no need for randomization of patients. 
(L1) There is no distinction between 
prognostic and predictive biomarker as 
patients are not randomized to 
experimental and control treatment arms. 
Also called: Nonrandomized clinical trial 
design, Uncontrolled Cohort 
Pharmacogenetic Study design 
 (A2) Simple logistics.  
Examples of actual trials: None identified a  (A3) Not complex statistical design  
  
(A4) In some cases, these designs may be viewed as 
ethical as all patients are given the opportunity to 
experience the experimental treatment. However, 
they may be viewed as unethical if the novel 
treatment does not benefit a subgroup of patients or 
causes adverse events. 
 
Enrichment designs (71 papers) [1,4,7-
9,11,13,15,16,18,19,21,23,25-33,36,42-86] (see 
Figure 3) 
Useful when we aim to test the 
treatment effect only in biomarker-
positive subset for which there is 
prior evidence that the novel 
treatment is beneficial, but the 
candidate biomarker requires 
prospective validation. 
(A5) Evaluates the effect of the experimental 
treatment in the biomarker-positive subgroup in a 
simple and efficient way. 
(L2) Do not assess whether the 
experimental treatment benefits the 
biomarker-negative patients, thus we 
cannot obtain information about this 
subgroup. Also unable to demonstrate 
whether the targeted treatment is 
beneficial in the entire study population. 
Also called: Targeted design, Selection 
design, Efficient Targeted design, 
Biomarker-Enrichment design, Marker-
enrichment design, Gene enrichment design, 
Enriched design, Clinically enriched Phase 
III study design, Clinically Enriched Trial 
design, Biomarker-Enriched design, 
Biomarker Enriched design, Biomarker 
Selected trial design, Screening enrichment 
design, Randomized Controlled Trial (RCT) 
of test positive design, Population 
enrichment design 
Useful when it is not ethical to assign 
biomarker-negative patients to the 
novel treatment for which there is 
prior evidence that it will not be 
beneficial for this subpopulation, or 
that it will harm them. 
(A6) Provides clear information about whether the 
novel treatment is effective for the biomarker-
positive subgroup, thus these designs can identify 
the best treatment for these patients and confirm the 
usefulness of the biomarker. 
(L3) Do not inform us directly about 
whether the biomarker is itself predictive 
because the relative treatment efficacy 
may be the same in the unevaluated 
biomarker-negative patients. Since these 
designs only enrol a subgroup of patients, 
they do not allow for full validation of the 
marker’s predictive ability. For full 
validation, a trial would need to 
randomize all patients in order to test for a 
treatment–biomarker interaction. 
Examples of actual trials: CRYSTAL [49], 
BRIM 3 [49-51], EURTAC [49], CLEOPATRA 
[49], PROFILE 1007 [49,50], LUX-Lung [49], 
NSABP B-31 and NCCTG N9831 
[4,15,16,18,19,28-31,36,44,46,52-60], CALGB-
Recommended when both the cut-off 
point for determination of biomarker-
status of patients and the analytical 
validity of a biomarker are well 
established. 
(A7) Reduced sample size as the assessment of 
treatment effect is restricted only to biomarker-
positive subgroup. Therefore, if the selected 
biomarker is “biologically correct” and reliably 
(L4) Researchers should carefully decide 
whether or not to follow this strategy as it 
may be of limited value due to the 
exclusion of biomarker-negative patients. 
It may be that the entire population could 
  
 
 
10603 [61], CATNON [62], CODEL [62], 
Evaluation of epidermal growth factor 
receptor variant III (EGFRvIII) peptide 
vaccination [62], N0923 [7,21] , Flex study 
[64], TOGA trial [47], IPASS [33,43], N0147 
[29], PetaCC-8 [29,47], C80405 [29], ECOG 
E5202 [29] 
measured, the used enrichment strategy could 
result in a large saving of randomized patients. 
benefit from the experimental treatment 
equally irrespective of biomarker status, in 
which case enrolling only the biomarker-
positive patients will result in slow trial 
accrual, increase of expenses and 
unnecessary limitation of the size of the 
indicated patient population. 
  (A8) Enables rapid accumulation of efficacy data. 
(L5) Concern over an ethical problem as 
we cannot include individuals in a clinical 
trial if it is believed that the treatment is 
not effective for them, as raised by the US 
Food and Drug Administration (FDA) 
[50]. It was based on the facts that the 
experimental treatment can only be 
approved for a particular biomarker-
defined subpopulation (i.e., biomarker-
positive patients) if a companion 
diagnostic test is also approved, and how 
the test can be approved if the Phase III 
trial does not show that the novel 
treatment does not benefit the biomarker-
negative patients. 
  
(A9) Allow us to avoid potential dilution of the 
results due to the absence of biomarker-negative 
patients. For example, if the design had included 
the biomarker-negative population and the 
biomarker positivity rate was low as compared to 
the biomarker negative rate, then the estimation of 
the overall treatment effectiveness could be diluted 
as it would be driven by the biomarker-negative 
subset.  
(L6) The accuracy of diagnostic devices 
used to identify the biomarkers, e.g., 
biomarker assays, is not always correct 
[45]. This can result in incorrect selection 
of biomarker-positive patients and 
therefore these patients will erroneously 
be enrolled in a trial yielding biased 
treatment effect estimates. For example, 
even when the experimental treatment 
works well for a specific subgroup, if the 
biomarker assay is not able to identify this 
subgroup robustly then a promising 
treatment may be abandoned. 
  
(A10) Can be attractive in terms of speed and cost, 
meaning that patients are provided with tailored 
treatment sooner. 
 
Marker Stratified designs (45 papers) 
[4,10,12,13,15-19,21,25-27,30,31,33,44-46,49-
Useful when there is evidence that 
the novel treatment is more effective 
in the positive biomarker-defined 
(A11) Ability to assess the treatment effect not only 
in the entire population but also in each biomarker-
defined subgroup. Thus, this design can find the 
(L7) In situations where there are several 
biomarkers and treatments this design 
may not be feasible as it involves 
  
 
 
51,53,58,61,62,66,68,71-74,79-81,84-93] (see 
Figure 4) 
subgroup than in the negative 
biomarker-defined subgroup but 
there is insufficient compelling data 
indicating that the experimental 
treatment does not benefit the 
biomarker-negative patients. 
optimal treatment in the entire population and in 
each biomarker-defined subgroup. 
randomization of patients between all 
possible treatment options and may 
require a large sample size. 
Also called: Marker-stratified design, 
Biomarker-stratified design, Stratified-
Randomized design, Stratification design, 
Stratified design, Stratified Analysis design, 
Marker by treatment – interaction design, 
Marker-by-treatment interaction design, 
Treatment by marker interaction design, 
Treatment-by-marker interaction design, 
Marker × treatment interaction design, 
Treatment-marker interaction design, 
Biomarker-by-treatment interaction design, 
Non-targeted RCT (stratified by marker) 
design, Genomic Signature stratified 
designs, Signature-Stratified design, 
Randomization or analysis stratified by 
biomarker status design, marker-interaction 
design. 
 
(A12) An ethical design even in situations where the 
biomarker is not useful as no treatment decisions 
are made based on biomarker status; all decisions 
are made randomly. Consequently, if the 
biomarker’s value is in doubt, this design may be 
preferred. 
(L8) May not be feasible when the 
prevalence of the biomarker is low. 
Examples of actual trials: MARVEL (N023) 
[4,16,30,31,33,44,61,89], GALGB-30506 
[15,61], RTOG0825 [45], EORTC 10994 p53 
[12,66], IBCSG trial IX [18], MINDACT [18]  
  
(L9) Might be expensive to test the entire 
population for its biomarker status. 
   
(L10) Measuring the biomarker up front 
may be logistically difficult. 
   
(L11) There is no guarantee of balanced 
groups for analysis. 
Sequential Subgroup-Specific design (11 
papers) [13,14,19,22,53,57,58,60,69,91,94] (see 
Figure 5) 
Recommended when prior evidence 
indicates that the biomarker-positive 
subpopulation benefits more from the 
novel treatment as compared to the 
biomarker-negative subpopulation.  
(A13) Allows for the estimation of treatment effect 
in biomarker-positive and biomarker-negative 
subgroups. 
(L12) Has less power when there is 
homogeneity of treatment across the 
different biomarker defined subgroups as 
compared to the overall/biomarker-
positive designs. 
Also called: sequential design, Fixed-
sequence 2 design, hierarchical fixed 
sequence testing procedure 
 
(A14) Preserves the overall type I error rates and 
allows for a smaller sample size than the parallel 
version mentioned below. 
(L13) Need a much larger sample size than 
the overall/biomarker positive designs if 
we assume that the treatment effect is 
relatively homogeneous across the 
biomarker-defined subsets. 
  
 
 
Examples of actual trials: PRIME [49], 
MARVEL [49] 
 
(A15) Considered as the best direct evidence for 
clinical decision making as it tests the treatment 
effectiveness in both the biomarker-positive and 
biomarker-negative subset in a sequential way. 
 
  
(A16) Do not require larger sample size than the 
overall/biomarker-positive designs when the 
prevalence of the biomarker-positive patients is 
small. 
 
Parallel Subgroup-Specific design (3 
papers) [14,49,69] (see Figure 6) 
Appropriate when the aim of the 
study is to give treatment 
recommendations for each 
biomarker-defined subgroup 
separately at the same time. 
(A17) Same as (A13), (A16) (L14) Same as (L12) 
Also called: Phase III Biomarker-Stratified 
design 
  
(L15) Allocates the overall level 𝑎 
between the two biomarker-defined 
subgroup tests which means that it will be 
more difficult to achieve statistical 
significance in the biomarker-positive 
subgroup. 
Examples of actual trials: None identified a    
Biomarker-positive and overall strategies 
with parallel assessment (8 papers) 
[1,14,36,47,49,69,95,96] (see Figure 7) 
Recommended when the aim of the 
study is to assess the treatment effect 
in both the entire population and in 
the biomarker-positive subset but not 
in the biomarker-negative 
population. 
(A18) Can control the overall type I error 𝑎. 
(L16) Can be overly conservative as in the 
SATURN trial because of the correlation 
between the test of treatment effect in the 
overall study population and in the 
biomarker subgroups. 
Also called: Overall/biomarker-positive 
design with parallel assessment, prospective 
subset design, hybrid design 
 
(A19) Can require smaller sample size as compared 
to the subgroup-specific designs, especially when 
we assume that the novel treatment equally benefits 
both biomarker-defined subgroups. 
(L17) Cannot control the probability of 
rejecting the null hypothesis of no 
treatment effect in the biomarker-negative 
subset when the treatment benefit is 
restricted to biomarker-positive patients. 
Consequently, there is a high risk of 
inappropriately recommending the novel 
treatment for biomarker-negative patients 
due to the large treatment effect in 
biomarker-positive subset. 
Examples of actual trials: S0819 [14,49], 
SATURN [14,36,47,49,95,96], MONET1 
[14,49], ARCHER [14,49], ZODIAC [49], 
MERiDiAN [49] 
   
  
 
 
Biomarker-positive and overall strategies 
with sequential assessment (11 papers) 
[13,14,30,44,49,69,80,84,85,88,94] (see Figure 
8) 
Might be useful in cases where the 
experimental treatment is expected to 
be effective in the overall population. 
(A20) Same as (A18), (A19) 
(L18) Can be problematic for determining 
whether the treatment is beneficial in the 
biomarker-negative subgroup. 
Also called: Overall/biomarker-positive 
design with sequential assessment, 
sequential design, Fixed-sequence 2 design, 
hierarchical fixed sequence testing 
procedure 
  (L19) Same as (L17) 
Examples of actual trials: Trial of letrozole 
plus lapatinib versus letrozole plus placebo 
in breast cancer, with the biomarker defined 
by human epidermal growth factor receptor 
2 (HER2) [14], N0147 [30,49] 
   
Biomarker-positive and overall strategies 
with fall-back analysis (15 papers) 
[10,30,36,44,47,49,53,57,60,69,84,88,94,96,97] 
(see Figure 9) 
Recommended when there is 
insufficient confidence in the 
predictive value of the biomarker and 
the novel treatment is assumed to 
probably benefit all patients. 
(A21) Can assess the treatment effect in the 
biomarker-positive patients, if no benefit is detected 
in the overall population. 
(L20) Same as (L17), (L18) 
Also called: Biomarker-stratified design 
with fall-back analysis, fall-back design, 
prospective subset design, sequential design, 
other analysis plan design, Fallback design 
 (A22) Same as (A18), (A19)  
Examples of actual trials: None identified a    
Marker Sequential test design (4 papers) 
[14,49,69,94] (see Figure 10) 
Recommended when biomarkers 
with strong credentials are available 
and we have convincing evidence 
that the novel treatment is more 
effective in biomarker-positive than 
in biomarker-negative patients. 
(A23) Can provide clear evidence of treatment 
benefit in the biomarker-positive subgroup and in 
the biomarker-negative subgroup. 
(L21) In situations where biomarker status 
is not available for some of the patients 
included in the study, this design can 
either exclude these patients or include 
them in the global test, however, further 
statistical adjustments might be required 
in that case. 
Also called: MaST design, hybrid design 
Appropriate when we can assume 
that the treatment will not be 
beneficial in the biomarker-negative 
subpopulation unless it is effective 
for the biomarker-positive 
subpopulation. 
(A24) Enables sequential testing of the treatment 
effect in the entire study population and in the 
biomarker-defined subgroups to restrict testing of 
the treatment effect in the entire population when 
there is no significant result in the biomarker-
positive subset, while controlling the appropriate 
type I error rates. 
(L22) Does not decrease the sample size of 
the study as it was developed in order to 
increase the power compared to the 
sequential subgroup-specific design in 
situations where the novel treatment 
benefits equally both biomarker-negative 
and biomarker-positive patients. 
Examples of actual trials: ECOG E1910 
[14,49] 
 
(A25) Results in higher power as compared to the 
sequential subgroup-specific design in cases where 
 
  
 
 
the treatment effect is homogeneous across the 
biomarker-defined subgroups. 
  
(A26) Preserves the power in situations where the 
treatment effect is restricted only to the biomarker-
positive patients and at the same time it controls the 
relevant type I error rates. 
 
  
(A27) Control the type I error rate for the 
biomarker-negative subgroup over all possible 
prevalence values. 
 
  
(A28) The probability of erroneously concluding 
that the novel treatment is beneficial for the entire 
population when the global effect is driven by the 
biomarker-positive patients is minimized since the 
design only tests the treatment effect in the entire 
population when no significant effect is detected in 
the biomarker-positive subgroup. 
 
Hybrid designs (14 papers) [1,13,15,29-
31,36,46,48,55,66,84,88,98] (see Figure 11) 
Can be used when there is prior 
evidence indicating that only a 
particular treatment is beneficial to a 
biomarker-defined subgroup which 
makes it unethical to randomize 
patients with that specific biomarker 
status to other treatment options. 
(A29) The feasibility of a prognostic biomarker can 
be tested. 
None found. 
Also called: Mixture design, Combination of 
trial designs, hybrid biomarker design 
 
(A30) Allows for better risk assessment and 
improved individualized treatment since it assigns 
patients to treatments based on risk assessment 
scores instead of their biomarker status (biomarker-
positive and biomarker-negative patients). 
 
Examples of actual trials: TAILORx 
[15,48,55,58,63,66], EORTC MINDACT 
[15,48,55,66], ECOG 5202 study [30,46] 
   
Biomarker-strategy designs with 
biomarker assessment in the control arm 
(21 papers) 
[15,25,26,32,33,36,45,61,62,64,79,82,85,86,92,9
3,99-103] (see Figure 12) 
Useful when we want to test the 
hypothesis that the treatment effect 
based on the personalized approach 
is superior to that of the standard of 
care. 
(A31) Biomarker can be validated without including 
all possible biomarker–treatment combinations [26] 
as in the non-biomarker-based arm all patients 
receive only the control treatment. 
(L23) Unable to inform us whether the 
biomarker is predictive as these designs 
are able to answer the question about 
whether the biomarker-based strategy is 
more effective than standard treatment, 
irrespective of the biomarker status of the 
study population. 
Also called: Marker strategy design, 
Biomarker-strategy design, Strategy design, 
Marker-based strategy design, Marker-based 
 
(A32) Have the option of testing the biomarker 
status of patients in the non-biomarker-strategy arm 
which can aid secondary analyses [26]. 
(L24) The evaluation of the true biomarker 
by treatment effect is not possible as the 
biomarker-positive patients receive only 
  
 
 
design, Random disclosure design, 
Customized strategy design, Parallel 
controlled pharmacogenetic study design, 
Marker-based strategy design I, Biomarker-
guided design, Biomarker-based assignment 
of specific drug therapy design, Marker-
based strategy I design, Biomarker-strategy 
design with a standard control, Marker 
strategy design for prognostic biomarkers 
the experimental treatment and not the 
alternative treatment (control treatment). 
Consequently, this design cannot detect 
the case in which the control treatment 
might be more beneficial for the entire 
population. 
Examples of actual trials: GILT docetaxel 
[15], Randomized phase III trial conducted 
in Spain, dedicated to patients with 
advanced Non-Small Cell Lung Cancer 
(NSCLC) candidates for first-line 
chemotherapy [32,64,100], Study the effect of 
Magnetic Resonance Imaging (MRI) in 
patients with low back pain on patient 
outcome and to evaluate Doppler US of the 
umbilical artery in the management of 
women with intrauterine growth retardation 
(IUGR), Randomized controlled trial in 
recurrent platinum-resistant ovarian 
carcinoma [101] 
 
(A33) Able to inform us whether the biomarker is 
prognostic. 
(L25) In case that the number of 
biomarker-positive patients is very small, 
then the treatment received will be similar 
in biomarker-strategy arm and non-
biomarker strategy arm. Consequently, the 
trial might give little information 
regarding the efficacy of the experimental 
treatment or it might not be able to detect 
it. As a result, this type of design should 
be used when there is an adequate number 
of biomarker-positive and biomarker-
negative patients.  
  
(A34) Can be expanded to investigate several 
biomarkers and treatments [103]. Additionally, 
these designs can be attractive when evaluating 
multiple biomarkers or the predictive value of 
molecular profiling between several treatment 
options is to be assessed [45]. 
(L26) Unable to compare directly 
experimental treatment to control 
treatment as the aim is to compare not the 
treatments but the biomarker-strategies.  
  
(A35) Might be used more frequently in the future 
due to the wide variety of molecular biomarkers, 
complexity of gene expression arrays, and several 
treatments directed at similar targets [103]. 
(L27) Less efficient designs than 
biomarker-stratified designs [4,73] and a 
poor substitute for clinical trials which aim 
to compare the experimental treatment to 
control treatment, since it is possible for 
some patients in both the biomarker-based 
strategy arm and non-biomarker-based 
strategy arm to be assigned to the same 
treatment (due to the existence of 
biomarker-negative patients in both 
strategy arms the treatment effect can be 
diluted) [51]. Consequently, as a large 
  
 
 
overlap of patients receiving the same 
treatment might have occurred, the 
comparison of the two biomarker-strategy 
arms results in a hazard ratio which is 
forced towards unity, i.e., no treatment 
effect exists as the effect of experimental 
versus control treatment is diluted by the 
biomarker-based treatment selection. For 
this reason, a large sample size is needed 
to detect at least a small overall difference 
in outcomes between the two biomarker-
strategy arms. 
   
(L28) Should be used only if you want to 
evaluate a complex biomarker-guided 
strategy with a variety of treatment 
options or biomarker categories [73]. 
Biomarker-strategy design without 
biomarker assessment in the control arm 
(14 papers) 
[9,13,17,18,20,25,36,38,61,74,101,104-106] (see 
Figure 13) 
In situations where it is not feasible 
or unethical to test the biomarker in 
the entire population. 
(A36) Galanis et al., 2011 [45] stated that these 
designs can be attractive when evaluating multiple 
biomarkers or the predictive value of molecular 
profiling between several treatment options is to be 
assessed. Also, Freidlin and Korn, 2010 [73] claimed 
that these biomarker-strategy designs should be 
used only if researchers want to evaluate a complex 
biomarker-guided strategy with a variety of 
treatment options or biomarker categories. 
(L29) Criticized for their potential cost 
increase due to the fact that patients 
without predicted responsive biomarker 
are double enrolled in the trial (biomarker-
negative patients receive control treatment 
in both strategy arms). 
Also called: Biomarker-strategy design with 
standard control, Direct-predictive 
biomarker-based, RCT of testing, Test-
treatment, Parallel controlled 
pharmacogenetic diagnostic study, Marker 
strategy, Marker-based with no 
randomization in the non-marker-based 
arm, Classical, Marker-based strategy, 
Marker strategy design for prognostic 
biomarkers 
 (A37) Same as (A31), (A32), (A33) 
(L30) Biomarker-positive and biomarker-
negative subpopulations might be more 
imbalanced as compared with the first 
type of biomarker-strategy design due to 
the fact that the randomization to different 
treatment strategies is performed before 
the evaluation of the biomarker status 
(balancing the randomization is useful to 
ensure that all randomized patients have 
tissue available). This can happen 
especially when the number of patients is 
very small. 
Examples of actual trials: A study, which 
evaluated the use of immediate computed 
tomography in patients with acute mild 
head injury [101,104]. 
  
(L31) Same as (L23), (L24), (L25), (L26), 
(L27) 
  
 
 
Biomarker-strategy design with treatment 
randomization in the control arm (17 
papers) 
[15,17,26,27,32,36,45,62,64,66,74,86,92,93,106-
108] (see Figure 14) 
In cases where we want to know 
whether the biomarker is not only 
prognostic but also predictive, these 
designs are preferable as compared to 
the two previously mentioned 
biomarker-strategy designs. 
(A38) These designs have the ability to inform 
researchers about the potential superiority of the 
control treatment in the whole population or among 
a particular biomarker-defined subpopulation. 
(L32) Generally require a larger sample 
size as compared to the marker-stratified 
designs. 
Also called: Biomarker-strategy design with 
a randomized control, Modified marker-
based strategy design (for predictive 
biomarkers), Biomarker-strategy design 
with randomized control, Marker-based 
design with randomization in the non-
marker-based arm, Marker-based strategy 
design II, Marker-strategy design, 
Augmented strategy design, Trial design 
allowing the evaluation of both the 
treatment and the marker effect 
 
(A39) Able to inform us whether the biomarker is 
prognostic or predictive.  
(L33) Same as (L27) 
Examples of actual trials: None identified a  
(A40) Allow clarification of whether the results 
which indicate efficacy of the biomarker-directed 
approach to treatment are caused due to a true 
effect of the biomarker status or to an improved 
treatment irrespective of the biomarker status. 
 
  (A41) Same as (A36)  
Reverse marker-based strategy (4 papers) 
[86,92,93,109] (see Figure 15) 
Enables testing the interaction 
hypothesis of treatment and 
biomarker in a more efficient way as 
compared to the first (i.e., Biomarker-
strategy design with biomarker 
assessment in the control arm) and 
third biomarker-strategy subtype 
design (i.e., Biomarker-strategy 
design with randomization in the 
control arm and the marker stratified 
design) 
(A42) Can estimate directly the marker-strategy 
response rate. 
(L34) It has been claimed by Baker, 2014 
[93] that other designs than the reverse 
marker-based strategy are more 
appropriate in order to investigate 
questions which include both treatment 
effect of biomarker-defined subgroups and 
the biomarker strategy treatment effect. 
These designs should allow the estimation 
of treatment effects within biomarker-
defined subgroups as well as the 
estimation of the global treatment effect. 
Also called: None found  
(A43) Allows the estimation of the effect size of the 
experimental treatment compared to the control 
treatment for each biomarker-defined subset 
separately. 
 
Examples of actual trials: None identified a  
(A44) There is no chance that the same treatment 
will be tailored to biomarker-positive patients who 
are randomized either to the biomarker-based 
 
  
 
 
strategy arm or the reverse marker strategy. Also, 
there is no possibility of the same treatment 
assignment to biomarker-negative patients who are 
randomly assigned to the two biomarker-based 
strategy arms. 
  
(A45) It has been demonstrated by Eng, 2014 [92] 
that this new type of design is more than four times 
more efficient for testing the interaction between 
treatment and biomarker compared to Biomarker-
strategy design with biomarker assessment in the 
control arm, Biomarker-strategy design with 
randomization in the control arm and the marker 
stratified design. 
 
A specific randomized phase II trial design 
that can be used to guide decision making 
for further development of an experimental 
therapy. (1 paper) [71] (see Figure 16) 
Recommended when we want to 
conduct a Phase II randomized trial 
which allows decisions to be made 
about which type of Phase III 
biomarker-guided trial should be 
used.  
(A46) Works well in providing recommendations 
for phase III trial design. 
None found 
a Although not found within the review, the design may be implemented in ongoing trials. 
Table 2. Sample size formulae for biomarker-guided clinical trial designs. 
Types of Biomarker-Guided 
Non-Adaptive Trial Designs 
Sample Size Formula Definition 
Single arm designs 
Standard sample size formula can be used, more information can be found in the ‘methodology’ part of the 
‘Single arm designs’ section in the main text. 
 
Enrichment designs 
[55,61,65,110-112] 
Online tool for sample size calculation when using either binary or time-to-event endpoints is available on 
the following website: http://brb.nci.nih.gov/brb/samplesize/td.html [113]. 
 
 𝐸(𝐷𝑖,𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡) =
𝑛𝑇𝜆𝑖
2(𝜆𝑖 + 𝜑𝑖)
{1 −
𝑒−(𝜆𝑖+𝜑𝑖)𝜏
(𝜆𝑖 + 𝜑𝑖)𝑇
[1 − 𝑒−(𝜆𝑖+𝜑𝑖)𝑇]} 
𝐸(𝐷𝑖,𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡) is referred to the 
expected number of events per 
treatment arm (time-to-event outcome), 
𝑖 corresponds to either the 
experimental or the control treatment 
group, 1: 1 ratio between the two 
treatment arms (experimental:control) 
is assumed, 𝜆 corresponds to the event 
hazard rate, 𝜑 is the loss to follow-up 
rate, 𝑇 denotes the accrual time, 
patients enter the trial according to a 
Poisson process with rate 𝑛 per year 
  
 
 
over the accrual period of 𝑇 years, τ 
corresponds to the follow-up period. 
 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 = 4 [
(𝑧𝛼/2 + 𝑧𝛽)
logθ1
]
2
 
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 is referred to the required 
total number of events (time-to-event 
outcome), 1: 1 ratio between the two 
treatment arms (experimental:control) 
is assumed, 𝑧𝛼/2, 𝑧𝛽 denote the upper 
𝛼/2- and upper 𝛽-points respectively of 
a standard normal distribution, 𝛼 and 
𝛽 denote the assumed type I error and 
type II error respectively, θ1 denotes 
the assumed hazard ratio between the 
two treatment groups (control vs 
experimental) in the biomarker-positive 
subset. 
 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 = 2?̅?𝑄(1 − ?̅?𝑄) [
(𝑧𝛼/2 + 𝑧𝛽)
(𝑝𝐴
𝑄 − 𝑝𝐵)
]
2
 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚  is referred to the 
required number of patients per 
treatment arm (binary outcome), 1: 1 
ratio between the two treatment arms 
(experimental:control) is assumed, 𝑝𝐴
𝑄 
and 𝑝𝐵 are the response probabilities in 
the experimental and control groups 
respectively, ?̅?𝑄 = (𝑝𝐴
𝑄 + 𝑝𝐵) 2⁄ . 
 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 =
2𝜎2(𝑧𝛼/2 + 𝑧𝛽)
2
(𝜇𝐴+ − 𝜇𝐵+)2
 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 is referred to the 
required total number of patients per 
treatment arm (continuous response 
endpoints), 1: 1 ratio between the two 
treatment arms (experimental:control) 
is assumed, 𝜎2 denotes the anticipated 
common variance, 𝜇𝐴+ and 𝜇𝐵+ the 
mean responses for biomarker-positive 
patients in the experimental and control 
treatment arm respectively. 
 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 = 2𝜎
2(𝑧𝛼/2 + 𝑧𝛽)
2
{𝜆1[(1 − 𝜔) 𝜁 + 𝜔]}
−2 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 is referred to the 
required total number of patients per 
treatment arm (continuous response 
endpoints when accounting for error in 
the assaying of the study population), 
1: 1 ratio between the two treatment 
arms (experimental:control) is assumed, 
𝜔 measures the accuracy of the assay 
  
 
 
and corresponds to the PPV (positive 
predictive value of the assay, i.e., the 
proportion of patients who are assigned 
biomarker positive status according to 
the assay who are truly biomarker 
positive), 𝜆1 is the treatment effect in 
the biomarker-positive patients and 𝜁 =
𝜆0 𝜆1⁄  (where 𝜆0 is the treatment effect 
in the biomarker-negative patients). 
Marker Stratified designs 
[31,53,60,92,111,112,114] 
Online tool for sample size calculation when using either binary or time-to-event endpoints is available on 
the following website: http://brb.nci.nih.gov/brb/samplesize/sdpap.html [115]. 
 
 𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 = 4
(𝑧𝑎1 + 𝑧𝛽)
2
[log (𝜃1)]2
+ 4
(𝑧𝑎2 + 𝑧𝛽)
2
[log (𝜃2)]2
 
𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑  is referred to the required 
total number of events for the 
achievement of sufficient power in each 
biomarker-defined subgroup separately 
(time-to-event endpoint), 1: 1 ratio 
between the two treatment arms 
(experimental:control) is assumed, 𝜃2 
corresponds to the hazard ratio of 
biomarker-negative subgroup, 𝑎1 =
𝑎2 = 𝑎 2⁄ . 
 𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 =
4(𝑧𝑎/2 + 𝑧𝛽)
2
[𝑘log(𝜃1) + (1 − 𝑘)log(𝜃2)]2
 
𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 is referred to the required 
total number of events for the 
achievement of sufficient power in the 
overall population (time-to-event 
endpoint), 𝑘 is the proportion 
biomarker-positive patients, 1: 1 ratio 
between the two treatment arms 
(experimental:control) is assumed. 
 𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 =
4(𝑧𝑎/2 + 𝑧𝛽)
2
{[𝑘𝑃𝑟(+)(𝑒𝑣𝑒𝑛𝑡)log(𝜃1) + (1 − 𝑘)𝑃𝑟(−)(𝑒𝑣𝑒𝑛𝑡)log(𝜃2)] √𝑘𝑃𝑟(+)(𝑒𝑣𝑒𝑛𝑡) + (1 − 𝑘)𝑃𝑟(−)(𝑒𝑣𝑒𝑛𝑡)⁄ }
2 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 is referred to the required 
total number of patients for the 
achievement of sufficient power in the 
overall population (time-to-event 
endpoint), 1: 1 ratio between the two 
treatment arms (experimental:control) 
is assumed, 𝑃𝑟(+)(𝑒𝑣𝑒𝑛𝑡), 𝑃𝑟(−)(𝑒𝑣𝑒𝑛𝑡) 
are the probabilities of an event in 
biomarker-positive subset and 
biomarker-negative subset respectively. 
  
 
 
 
𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
=
[log(𝜃1)]
2
[𝑘log(𝜃1) + (1 − 𝑘)log(𝜃2)]2
=
1
[𝑘 + (1 − 𝑘)
log(𝜃2)
log(𝜃1)
]
2 
𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
 is referred to the ratio of the 
required number of events between 
marker stratified and enrichment 
design (time-to-event endpoint). 
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
≈
1
[𝑘 + (1 − 𝑘)
𝛿−
𝛿+
]
2 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
 is referred to the ratio of the 
required number of patients between 
marker stratified and enrichment 
design (binary outcome), 𝛿−, 𝛿+, 
correspond to the treatment 
effectiveness in biomarker-negative and 
biomarker-positive subgroup 
respectively. 
 𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 = 2(𝑧𝑎 + 𝑧1−𝛽)
2
{
𝑟𝐴+(1 − 𝑟𝐴+) + 𝑟𝐵+(1 − 𝑟𝐵+)
(𝛽𝐴 + 𝛽𝐼)2
+
𝑟𝐴−(1 − 𝑟𝐴−) + 𝑟𝐵−(1 − 𝑟𝐵−)
(𝛽𝐴)2
} 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 is referred to the required 
total number of patients (binary 
outcome), 𝛽0 denotes a baseline effect, 
𝛽𝐴 denotes the added effect of the 
experimental treatment, 𝛽+ denotes the 
biomarker-positive effect and 𝛽𝐼 
denotes the nonadditive effect, 𝛼 
corresponds to the target level, 1 − 𝛽 
corresponds to the power, 𝑟𝐴+, 𝑟𝐵+ are 
the assumed response rates of 
biomarker-positive patients receiving 
the experimental and the control 
treatment respectively, 𝑟𝐴−, 𝑟𝐵− are the 
assumed response rates of biomarker-
negative patients receiving the 
experimental and the control treatment 
respectively. 
Sequential Subgroup-
Specific design [57] 
𝑁𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
+ = 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 
𝑁𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
+  is referred to 
the required number of biomarker-
positive patients (binary outcome), 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 is the required number of 
biomarker-positive patients (binary 
outcome) in the enrichment design. 
 𝑁𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 =
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
𝑘
 
𝑁𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 is referred to 
the required total number of patients 
(binary outcome), 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 is the 
required number of biomarker-positive 
  
 
 
patients (binary outcome) in the 
enrichment design. 
 𝑁𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
− =
(1 − 𝑘)𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
𝑘
 
𝑁𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
−  is referred to 
the required number of biomarker-
negative patients (binary outcome), 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 is the required number of 
biomarker-positive patients (binary 
outcome) in the enrichment design. 
 𝐷𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
+ = 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 
𝐷𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
+  is referred to 
the required number of events for 
biomarker-positive patients (time-to-
event outcome), 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 is the 
required number of events for 
biomarker-positive patients (time-to-
event outcome). 
 𝐷𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
− = 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 (
𝜆−
𝜆+
) (
1 − 𝑘
𝑘
) 
𝐷𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
−  is referred to 
the required number of events for 
biomarker-negative patients (time-to-
event outcome), 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 is the 
required number of events for 
biomarker-positive patients (time-to-
event outcome), 𝜆−, 𝜆+, are the event 
rates in biomarker-negative and 
biomarker-positive control subgroups. 
Parallel Subgroup-Specific 
design 
Same formula proposed for marker stratified designs could be considered to achieve sufficient power in 
each biomarker-defined subgroup simultaneously. However, in order to control the overall type I error rate 
of the design at the overall level of significance 𝛼 it is required to allocate this overall 𝛼 between the test for 
the biomarker-positive subgroup and the test for the biomarker-negative. Consequently, for biomarker-
positive subgroup the reduced significance level 𝑎1 = 𝑎 − 𝑎2 can be used whereas the reduced significance 
level 𝑎2 = 𝑎 − 𝑎1 can be used for biomarker-negative subgroup. 
 
Biomarker-positive and 
overall strategies with 
parallel assessment 
If there is significant confidence that the biomarker is predictive, the sample size estimation is aimed at 
having a sufficient number of biomarker-positive individuals to enable the treatment effect in the biomarker 
positive subgroup to be detected. Standard formula for sample size calculation of biomarker-positive 
subgroup proposed for the enrichment designs could be considered by using the reduced significance level 
𝑎1 = 𝑎 − 𝑎2. On the other hand, if there is no confidence in the predictive value of the biomarker, the sample 
size estimation is aimed at having a sufficient number of patients to detect a treatment effect in the overall 
study population; consequently, for the sample size calculation, the same formula proposed for marker 
stratified designs aiming to achieve sufficient power in the overall population could be applied by using the 
reduced significance level 𝑎2 = 𝑎 − 𝑎1. 
 
  
 
 
Biomarker-positive and 
overall strategies with 
sequential assessment 
At the first stage, the standard formula for a traditional randomized trial which is the same with the formula 
proposed for enrichment designs can be applied for the biomarker-positive subgroup. At the second stage, 
the sample size formula proposed for marker stratified designs aiming to yield appropriate power for the 
entire population could be considered. 
 
Biomarker-positive and 
overall strategies with fall-
back analysis 
At the first stage, the sample size formula proposed for marker stratified designs aiming to yield 
appropriate power for the entire population could be considered by using the reduced significance level 
𝑎1 = 𝑎 − 𝑎2. At the second stage, the formula proposed for enrichment designs could be applied for the 
biomarker-positive subgroup by using the reduced significance level 𝑎2 = 𝑎 − 𝑎1. 
 
Marker Sequential test 
design (MaST)  
A standard sample size calculation (i.e., the same sample size calculation as for the enrichment designs) can 
be applied for the biomarker-positive subpopulation. However, in order to have sufficient number of 
biomarker-positive patients to detect treatment effectiveness in that particular biomarker-defined subset and 
consequently to reach the desired power, the sample size should be calculated by using the reduced 
significance level 𝑎1 [0, 𝑎] instead of the global significance level 𝛼 which is used in the sample size 
formulae of the enrichment designs. The same formula could be considered for the sample size calculation 
of the biomarker-negative subgroup; however, the corresponding hazard ratio of that subgroup and the 
global significance level 𝛼 should be used. For the sample size calculation of the entire population, the same 
formula proposed for marker stratified designs aiming to achieve sufficient power in the overall population 
could be considered by using the reduced significance level 𝑎2 = 𝑎 − 𝑎1. 
 
Biomarker-strategy, design 
with biomarker assessment in 
the control arm [26,61,92] 
𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼 = 4 [
(𝑧𝛼/2 + 𝑧𝛽)
𝑘logθ1
]
𝟐
 
𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼 is referred to the required 
total number of events (time-to-event 
outcome), 1: 1 ratio between the two 
treatment arms (experimental:control) 
is assumed.  
 𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼 =
2(𝑧1−𝛼/2 + 𝑧1−𝛽)
2
(𝜏𝑚
2 + 𝜏𝑛
2)
(𝑣𝑚 − 𝑣𝑛)2
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼 is referred to the required 
total sample size (continuous clinical 
endpoints), 1: 1 ratio between the two 
treatment arms (experimental:control) 
is assumed, 𝑧1−𝛼/2, 𝑧1−𝛽 denote the 
lower 1 − 𝛼/2- and lower 1 − 𝛽-points 
respectively of a standard normal 
distribution, 𝑣𝑚 and 𝑣𝑛 denote the 
mean response from the biomarker-
based strategy arm and the non-
biomarker-based strategy arm 
respectively, and 𝜏𝑚
2 ,  𝜏𝑛
2 denote the 
variance of response for the biomarker-
based strategy arm and non-biomarker-
based strategy arm respectively. 
 𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼/𝑎𝑟𝑚 =
(𝑧𝑎 + 𝑧1−𝛽)
2
[𝑔1(1 − 𝑔1) + 𝑔2(1 − 𝑔2)]
Δ2
2  
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼/𝑎𝑟𝑚 is referred to the required 
total number of patients per arm 
(binary outcome), 𝑔1 is the expected 
  
 
 
response rate in the biomarker-based 
strategy arm, 𝑔2 is the expected 
response rate in the non biomarker-
based strategy arm, ∆2= 𝑔1 − 𝑔2, 
𝑔1, 𝑔2 can be found by calculating the 
formulae 𝑘𝑟𝐴+ + (1 − 𝑘)𝑟𝐵− and 𝑟𝐵 
respectively, 𝑟𝐵 denotes the marginal 
effect of treatment B (control treatment). 
Biomarker-strategy design 
without biomarker 
assessment in the control arm 
Same formulae as for the ‘Biomarker-strategy design with biomarker assessment in the control arm’ can be 
considered. 
 
Biomarker-strategy design 
with treatment 
randomization in the control 
arm [26,31,92] 
𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼 =
4(𝑧𝑎/2 + 𝑧𝛽)
2
{log [
2𝑘𝑚𝐵+ + 2(1 − 𝑘)𝑚𝐴−
𝑘(𝑚𝐴++𝑚𝐵+) + (1 − 𝑘)(𝑚𝐴−+𝑚𝐵−)
]}
2 
𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼 is referred to the required 
total number of events (time-to-event 
outcome), 1: 1 ratio between the two 
treatment arms (experimental:control) 
is assumed, 𝑚𝐴+, 𝑚𝐴−, 𝑚𝐵+, 𝑚𝐵−, denote 
the median survival for biomarker-
positive and biomarker-negative 
patients receiving control and 
experimental treatments respectively. 
 𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼 =
2(𝑧1−𝛼/2 + 𝑧1−𝛽)
2
(𝜏𝑚
2 + 𝜏𝑛𝑟
2 )
(𝑣𝑚 − 𝑣𝑛𝑟)2
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼 is referred to the required 
total sample size (continuous clinical 
endpoints), 1: 1 ratio between the two 
treatment arms (experimental:control) 
is assumed, 𝑣𝑛𝑟 denotes the mean 
response from the non-biomarker-based 
strategy arm, 𝜏𝑛𝑟
2  denotes the variance 
of response for the non-biomarker-
based strategy arm respectively. 
 𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼/𝑎𝑟𝑚 =
(𝑧𝑎 + 𝑧1−𝛽)
2
[𝑔1(1 − 𝑔1) + 𝑔3(1 − 𝑔3)]
Δ3
2  
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼/𝑎𝑟𝑚 is referred to the 
required total number of patients per 
arm (binary outcome), 𝑔3 is the 
expected response rate in the non 
biomarker-based strategy arm and ∆3=
𝑔1 − 𝑔3, the expected response 
rate 𝑔3 can be found by calculating the 
formula 𝑟𝐴 2⁄ + 𝑟𝐵 2⁄ , 𝑟𝐴 denotes the 
marginal effect of treatment A 
(experimental treatment).  
Reverse marker-based 
strategy [92] 𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝑉/𝑎𝑟𝑚 =
(𝑧𝑎 + 𝑧1−𝛽)
2
[𝑔1(1 − 𝑔1) + 𝑔4(1 − 𝑔4)]
Δ4
2  
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝑉/𝑎𝑟𝑚 is referred to the 
required total number of patients per 
  
 
 
arm (binary outcome), 𝑔4 is the 
expected response rate in the reverse 
biomarker-based strategy arm and Δ4 =
𝑔1 − 𝑔4, the expected response 
rate 𝑔4 can be found by calculating the 
formula 𝑘𝑟𝐵+ + (1 − 𝑘)𝑟𝐴−, 𝑟𝐵+, 𝑟𝐴− are 
the assumed response rates of 
biomarker-positive patients receiving 
the control treatment and biomarker-
negative patients receiving the 
experimental treatment.  
Randomized Phase II trial 
design with biomarkers [71] 
Online tool for sample size calculation is available on the following website: 
http://brb.nci.nih.gov/Data/FreidlinB/RP2BM [116]. 
 
  
 
2.1. Single Arm Designs 
Single arm designs were referred to in seven papers (7%). In the context of biomarkers, these 
designs (Phase II designs) include the whole study population to which the same experimental 
treatment is prescribed, without taking into consideration biomarker status.  
Design: In this design all patients are prescribed the experimental treatment and there is no 
comparison with a control treatment. These trial designs aid in the identification of association 
between biomarker status and the efficacy or safety of the experimental treatment. An illustration of 
this approach is shown in Figure 2. 
 
Figure 2. Single arm designs. 
Utility: These designs can be useful for the initial identification and/or validation of a biomarker 
and their aim is not to estimate the treatment effect in a definitive way but to identify whether the 
biomarker is sufficiently promising to proceed to a definitive Phase III biomarker-guided randomized 
controlled trial. 
Methodology: In single arm designs first we assess the biomarker status of patients and then as 
all patients will be treated the same way we could compare the outcome of the biomarker-positive 
subgroup with the outcome of biomarker-negative subgroup. According to Tajik et al., 2012 [117], in 
terms of the required sample size, a standard formula can be used, however one should take into 
consideration the multiple testing issue that arise due to the exploration of several prognostic 
biomarkers (e.g., Bonferroni adjustment or normal exact method to protect against type I error 𝑎 for 
multiple tests are often considered [118]). Further information can be found in the paper of 
Zaslavasky and Scott, 2012 [118] who studied the sample size estimation in single arm clinical trials 
with multiple testing under frequentist and Bayesian framework. 
Statistical considerations: The single arm approach can be considered as a simple statistical 
design as there is no need for randomization. However one limitation of this strategy is that there is 
no distinction between prognostic and predictive biomarkers i.e., as patients are not randomized to 
experimental and control treatment groups, it is not possible to determine whether an observed effect 
is attributable to the natural disease progression or to the treatment. Consequently, this study designs 
are unable to show the benefit of a biomarker with regard to the best choice of treatment. 
2.2. Enrichment Designs 
Enrichment designs are described in 71 papers (71%), either in Phase II or Phase III clinical trials, 
and involve randomizing only the biomarker-positive patients and comparing the experimental 
treatment versus the standard treatment only in this particular biomarker-defined subgroup. 
Design: Figure 3 graphically represents the trial design. First, the entire population is screened 
in order to identify the biomarker status of each patient. Next, the random assignment of individuals 
to different treatment arms is restricted only to the biomarker-positive subgroup. More precisely, 
biomarker-negative patients are excluded from the study and consequently, the assessment of the 
  
 
effectiveness of the experimental treatment is limited to the biomarker-positive subgroup. Thus, other 
patients apart from the biomarker-positive subpopulation can receive only the standard treatment 
(i.e., control treatment), but they are not included in the investigation during the trial design. The 
biomarker in this design is referred to as either the ‘selection’ or ‘enrichment’ biomarker. 
 
Figure 3. Enrichment designs. “R” refers to randomization of patients. 
Utility: Enrichment designs are useful for clinical trials aiming to test the treatment effect in a 
specific biomarker-defined subpopulation where there is evidence to suggest that effectiveness is 
limited to those within that subgroup, but the candidate biomarker still requires prospective 
validation. This design is recommended when both the cut-off point for determination of biomarker 
status of patients and the analytical validity of the biomarker have been well established. A rapid 
turnaround time for assessing the biomarker status of a patient is also needed to avoid any delay in 
treatment initiation. This strategy is particularly useful where it is unethical to randomize the 
biomarker-negative population into different treatment arms, for example where there is prior 
evidence that the experimental treatment is not beneficial for biomarker-negative individuals, or is 
likely to cause them harm. However, when it remains unclear whether or not biomarker-negative 
individuals will benefit from the novel treatment, the enrichment design is not appropriate and 
alternative designs, which also assess effectiveness in the biomarker-negative individuals, should be 
considered (e.g., randomize-all designs).  
Methodology: An online tool has been developed by Zhao and Simon [19,28,53,57,60] that 
allows sample size planning for the enrichment design both for binary and time-to-event (survival) 
outcomes, and is available at http://brb.nci.nih.gov/brb/samplesize/td.html [113]. For the purpose of 
estimating the sample size in the case of a survival outcome, data are simulated based on a marker 
stratified design (see next section for further information) in which both biomarker-positive and 
biomarker-negative subgroups are investigated in the study and formulae for the enrichment design 
described in the paper of Rubinstein et al., 1981 [110] are used. Furthermore, an exponential 
distribution of survival for the experimental and control treatment groups within both the biomarker-
positive and biomarker-negative subpopulations is assumed. More precisely, Rubinstein et 
al.provide the formula of the expected number of events per treatment group allowing to include 
exponential loss to follow-up given the following assumptions: (i) patients enter the trial according 
to a Poisson process and patient entry times will be independent and identically distributed 
uniformly over [0, 𝑇] where 𝑇 denotes the accrual time. Consequently, given the total number of 
patients 𝑁, the times from entry to the end of the trial will be independent and identically distributed 
uniformly over [𝜏, 𝑇 + 𝜏], where 𝜏 denotes the follow-up time and 𝑇 + 𝜏 the total duration of the 
study and (ii) 1:1 randomization between experimental and control treatment group is considered. 
The expected number of events per treatment arm according to Rubinstein et al. is given by 
  
 
𝐸(𝐷𝑖,𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡) =
𝑛𝑇𝜆𝑖
2(𝜆𝑖 + 𝜑𝑖)
{1 −
𝑒−(𝜆𝑖+𝜑𝑖)𝑡
(𝜆𝑖 + 𝜑𝑖)𝑇
[1 − 𝑒−(𝜆𝑖+𝜑𝑖)𝑇]}, (1) 
where 𝑖 corresponds to either the experimental or the control treatment group, 𝜆 corresponds to the 
event hazard rate, 𝜙 is the loss to follow-up rate and patients enter the trial according to a Poisson 
process with rate 𝑛 per year over the accrual period of 𝑇 years. However, the required total number 
of events in the two treatment groups (experimental and control treatment group) is given by 
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 = 4 [
(𝑧𝛼/2 + 𝑧𝛽)
logθ1
]
2
, (2) 
where  𝜃1  denotes the assumed hazard ratio between the two treatment groups (control vs. 
experimental) in the biomarker-positive subset and the constants 𝑧𝛼/2, 𝑧𝛽 denote the upper 𝛼/2- and 
upper 𝛽-points respectively of a standard normal distribution where 𝛼 and 𝛽 denote the assumed 
type I error and type II error respectively. Freidlin et al., 2010 [61] provided the aforementioned 
formula assuming that all random assignments use 1:1 randomization. As in a traditional 
randomized controlled trial, if the randomization is not equal, i.e., the ratio of allocation to treatment 
and control is 𝑅: 1 rather than 1:1, the aforementioned formula for the required total number of 
events 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡  which assumes 1:1 randomization can be multiplied by (𝑅 + 1)
2 4𝑅⁄  [119]. 
Consequently, the “4” in the formula of 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡  becomes (𝑅 + 1)
2 R⁄  and the corresponding 
formula for the total number of events becomes 
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 =
(𝑅 + 1)2
𝑅
[
(𝑧𝛼/2 + 𝑧𝛽)
logθ1
]
2
. (3) 
In a survival study, the calculation of the total sample size in terms of number of patients 
required in the two treatment groups (experimental and control treatment group) to be enrolled in 
order to yield the aforementioned total number of events depends on the probability of event over 
the duration of the study [120]. Consequently, the actual number of patients required in a survival 
study can be given by 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 =
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
Pr(𝑒𝑣𝑒𝑛𝑡)
, (4) 
where Pr(𝑒𝑣𝑒𝑛𝑡) is the probability of observing an event in the two treatment groups in the study 
and 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 is the required total number of events. Pr(𝑒𝑣𝑒𝑛𝑡) in a survival study can be given 
by 
Pr(𝑒𝑣𝑒𝑛𝑡) = 𝜋𝐴𝑃𝑟𝐴(𝑒𝑣𝑒𝑛𝑡) + 𝜋𝐵𝑃𝑟𝐵(𝑒𝑣𝑒𝑛𝑡), (5) 
where 
𝜋𝐴 =
𝑅
𝑅 + 1
 and 𝜋𝐵 =
1
𝑅 + 1
, (6) 
are the proportions of patients who are randomized to experimental and control treatment group 
respectively and 𝑃𝑟𝐴(𝑒𝑣𝑒𝑛𝑡)  and 𝑃𝑟𝐵(𝑒𝑣𝑒𝑛𝑡)  are the probability of events in experimental and 
control arm respectively [121]. Freedman, 1982 [122] provided an approximation of the probability of 
event for each treatment group assuming equal follow-up for all patients and thus simultaneous 
accrual for all patients whereas Schoenfeld, 1983 [123] provided a more exact approximation of the 
expected event rate as compared to Freedman’s approximation. More precisely, according to 
Freedman’s idea, 
𝑃𝑟𝑖(𝑒𝑣𝑒𝑛𝑡) ≈ 1 − 𝑆𝑖(𝜏) (7) 
and according to Schoenfeld’s idea, 
𝑃𝑟𝑖(𝑒𝑣𝑒𝑛𝑡) ≈ 1 − {𝑆𝑖(𝜏) + 4𝑆𝑖(𝑇 2⁄ + 𝜏) + 𝑆𝑖(𝑇 + 𝜏)}/6, (8) 
  
 
where 𝑖 denotes the corresponding treatment group (either experimental or control), 𝜏 denotes the 
follow-up time and 𝑇 the accrual period, 𝑇/2 + 𝜏 denotes the median follow-up time and 𝑇 + 𝜏 
denotes the total duration of the study. Another approximation of the probability of event could be 
𝑃𝑟𝑖(𝑒𝑣𝑒𝑛𝑡) ≈ 1 − 𝑆𝑖(𝑇 2⁄ + 𝜏) (9) 
considering that the survival probability can be approximated as the probability that a patient 
survives past the median follow-up time (i.e., 𝑇 2⁄ + 𝜏) [121]. 
The web-based interface is composed of two options. If the first option is chosen, the treatment 
effects for assay-negative and assay-positive patients must be specified in order to evaluate the 
relative efficiency of enrichment and untargeted design, i.e., marker stratified design (see next section 
for further information) in which apart from the biomarker-positive patients, biomarker-negative 
patients are also included; if the second option is chosen, it is possible to account for error in the 
assaying of the study population, thus, both the treatment effects for target-negative and target-
positive patients must be specified as well as the assay’s sensitivity and specificity. 
The sample size calculation using binary data is based on the formulas described by Simon and 
Maitournam [65,111,112] and again the two options offered when assuming a time-to-event outcome 
are available, i.e., options both with and without accounting for error in assaying the study 
population the biomarker status. When binary outcome is assumed and the allocation ratio is 1:1, the 
sample size of randomized patients required in each treatment arm (experimental and control) can 
be given as 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 = 2?̅?𝑄(1 − ?̅?𝑄) [
(𝑧𝛼/2 + 𝑧𝛽)
(𝑝𝐴
𝑄 − 𝑝𝐵)
]
2
, (10) 
where 𝑝𝐴
𝑄  and 𝑝𝐵  are the response probabilities in the experimental and control groups 
respectively, 
?̅?𝑄 =
𝑝𝐴
𝑄 + 𝑝𝐵
2
 (11) 
and 𝑧𝛼/2, 𝑧𝛽  denote the upper 𝛼/2 - and upper 𝛽 -points respectively of a standard normal 
distribution where 𝛼 and 𝛽 denote the assumed type I error and type II error respectively. The 
response probability in the experimental group can be found by 
𝑝𝐴
𝑄 = 𝑝𝐵 + 𝛿+, (12) 
where 𝛿+  denotes the improvement in response probability for biomarker-positive patients. 
Consequently, the total sample size of randomized patients will be 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 = 2𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 (13) 
For continuous response endpoints the aforementioned formula 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 changes to 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 =
2𝜎2(𝑧𝛼/2 + 𝑧𝛽)
2
(𝜇𝐴+ − 𝜇𝐵+)2
, (14) 
where 𝜎2  denotes the anticipated common variance, 𝜇𝐴+  and 𝜇𝐵+  the mean responses for 
biomarker-positive patients in the experimental and control treatment arm respectively. These 
formulae are the standard formulae used for a standard randomized trial. 
In addition, if we want to account for error in the assaying of the study population, the number 
of patients to be randomized in each arm of the enrichment trial when using continuous response 
endpoints can be given by the following formula 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 = 2𝜎
2(𝑧𝛼/2 + 𝑧𝛽)
2
{𝜆1[(1 − 𝜔) 𝜁 + 𝜔]}
−2 (15) 
where  𝜔 measures the accuracy of the assay and corresponds to the PPV (positive predictive value 
of the assay, i.e., the proportion of patients who are assigned the biomarker-positive status according 
  
 
to the assay who are truly biomarker positive), 𝜆1 is the treatment effect in the biomarker-positive 
patients and 𝜁 = 𝜆0 𝜆1⁄  (where 𝜆0 is the treatment effect in the biomarker-negative patients) [55]. 
Simon and Maitournam [65,111,112] considered that apart from the number of patients to be 
randomized, the number of patients needed to be screened should be also reported. Thus, they stated 
that the expected number of patients to be screened in the enrichment design is 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑘 where 
𝑘 corresponds to the proportion of biomarker-positive patients. The online tool developed by Zhao 
and Simon provides both the number of patients to be screened and to be randomized. 
Statistical considerations: Simon and Maitournam [65,111,112] undertook a simulation study, 
assuming a binary outcome, to compare power of the enrichment design with an untargeted design 
(i.e., marker stratified design, see next section for further information) in which all patients are 
randomized without measuring the biomarker. They concluded that the efficiency of the enrichment 
design relies both on the prevalence of the biomarker-positive patients and on the accuracy of the 
assay. Whilst in the situation where the assay cut-off point is not well established, there is a risk of 
severely compromising the power of the trial when using an enrichment design, if fewer than half of 
the entire study population are biomarker-positive and there is robust evidence that the experimental 
treatment does not benefit the biomarker-negative patients, the required number of randomized 
patients to allow sufficient power to detect a significant treatment effect is much smaller in the 
enrichment design than in the untargeted trial design. However, in the latter situation a greater 
number of individuals would need to be screened when using the enrichment design, and accruing 
the required number of biomarker positive patients could take a longer period of time. More 
precisely, Simon and Maitournam showed that an approximation of the ratio of the required number 
of patients to be randomized for the untargeted trial design as compared with the required number 
of patients randomized in the enrichment design when using binary outcome can be given by the 
following equation 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
≈
1
[𝑘 + (1 − 𝑘)
𝛿−
𝛿+
]
2 = [
𝛿+
𝑘𝛿+ + (1 − 𝑘)𝛿−
]
2
, 
(16) 
where 𝑘  denotes the proportion of biomarker-positive patients, 𝛿−  and 𝛿+  correspond to the 
treatment effectiveness (i.e., improvement in response probability) in biomarker-negative and 
biomarker-positive subgroups respectively. Consequently, in the situation where it is known that the 
novel treatment does not benefit the biomarker-negative patients at all, the ratio of the number of 
patients needed for randomization in the untargeted design relative to the number of patients 
required for the enrichment design is approximately 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
≈
1
𝑘2
, (17) 
as 𝛿− = 0. For example, if half of patients are biomarker-positive (𝑘 = 0.5) then a quarter of those 
needed to be randomized to the untargeted design trial would need to be randomized to the 
enrichment design trial. In cases where the novel treatment is half as effective in biomarker-negative 
patients as in the biomarker-positive patients (i.e., 𝛿− 𝛿+⁄ = 1/2), the aforementioned ratio changes 
to 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
≈
4
(𝑘 + 1)2
. (18) 
2.3. Randomize-All Designs 
Randomize-all designs (also named as all-comers/untargeted/unselected/non-targeted/simple 
randomization designs) allow the inclusion of the entire population as eligible for randomization. 
Consequently, the whole study population who meet the eligibility criteria, is randomly assigned to 
the different treatment groups (experimental and control treatment group) regardless of biomarker 
status. This design allows assessment of treatment benefit for the entire population irrespective of 
  
 
biomarker status whilst at the same time allowing for treatment benefit to be tested in the two 
biomarker-defined subgroups separately. 
Generally, they are useful when we are uncertain about the benefit of the experimental treatment 
in the overall population versus the biomarker-defined subgroups, the targeted treatment may 
benefit both biomarker-positive and biomarker-negative patients, the goal is to test the predictive 
ability of a biomarker, the assay reproducibility and accuracy is questionable, the turnaround time 
for biomarker assessment is long and the biomarker prevalence is high. 
Randomize-all designs are composed of two main subtypes: the Marker-stratified designs and 
the Hybrid designs, which are discussed separately below. 
2.3.1. Marker Stratified Designs 
These designs (prospective validation Phase III trials) were identified in 45 papers (45%) of our 
review. 
Design: An illustration of the design is shown in Figure 4. Individuals are stratified into 
biomarker-positive and biomarker-negative subgroups according to the results of the biomarker 
assessment and then they are randomized either to the experimental or to the control treatment 
group. The biomarker status in the Marker-Stratified design acts as a stratification factor where 
stratification is used to ensure balance across treatment groups with regard to biomarkers. Only 
individuals with valid biomarker results enter the trial. Consequently, we have four treatment 
groups, i.e., biomarker-positive patients assigned to either the experimental treatment arm or the 
control treatment arm and biomarker-negative patients assigned to either the experimental treatment 
arm or the control treatment arm. Thus, we can assess the relationship between treatment effect and 
biomarker status. 
 
Figure 4. Marker Stratified designs. “R” refers to randomization of patients. 
Utility: When there is enough evidence that the experimental treatment is more effective in the 
positive biomarker-defined subgroup than in the negative biomarker-defined subgroup but there is 
no sufficient compelling data that the experimental treatment is of no benefit in biomarker-negative 
individuals, the marker stratified design can be used. 
Methodology: Biomarker status is used to stratify the randomization, rather than to restrict 
eligibility. Marker-stratified designs can be conducted using two different testing plans; the so-called 
marker-by-treatment interaction with separate tests and marker-by-treatment interaction with 
interaction test. Both of these approaches involve conducting two independent clinical trials. 
Marker-by-treatment interaction using separate test was referred to in 15 papers (15%) of our 
review [4,11,12,15,29,42,45,53,57,60,80,82,84,87,88] and is also referred to as ‘separate randomization 
design’ and ‘separate by treatment interaction design’. This analysis plan is based on separate 
superiority tests in each biomarker-defined subgroup in order to detect the treatment efficacy in each 
subset. Two examples of actual trials which use this testing plan are the following: National Cancer 
  
 
Institute (NCI)-sponsored North Central Cancer Treatment Group Study N0975 [29] and the 
MARVEL trial [29]. 
The ‘marker-by-treatment interaction design using separate tests’ is a testing plan which 
determines whether the novel treatment is superior to the control treatment separately within each 
biomarker-defined subgroup. Consequently, the hypothesis to be tested, the calculation of the 
number of patients required for the trial, the estimation of the statistical power of the design and the 
randomization procedure of patients to different treatments are independent among the different 
subgroups [12]. The sample size of the trial should be calculated in such a way so as to yield adequate 
statistical power when testing whether the experimental treatment is superior to the control treatment 
separately in the two biomarker-defined subgroups. Hence, this approach is not widely used due to 
the required large sample size as essentially two separate trials are being conducted. Another 
limitation of this approach is that when multiple biomarker-defined subsets and treatments are to be 
investigated, it is difficult to implement in practice. 
The ‘marker-by-treatment interaction using interaction test’ uses a test for interaction between 
the biomarker status and treatment assignment and was identified in 12 papers (12%) of our review 
[4,12,15,42,53,57,60,82,84,87,88,94]. A marker stratified design which uses this testing plan is also 
referred to in the literature as an ‘interaction design’ or ‘genomic signature stratified design’. First, a 
formal statistical test for interaction between biomarker status and treatment assignment is 
undertaken. If this interaction is not significant, then the study is continued by testing the different 
treatments overall at a two-sided significance level of 0.05, otherwise, the treatments are compared 
within each biomarker-defined subpopulation at a two-sided 0.05 significance level (i.e., the same as 
in the marker-by-treatment interaction design using separate tests). The sample size for this second 
testing plan is calculated with reference to the treatment effect in the entire study population. 
Therefore, it might not provide sufficient power for detecting the treatment effect in each biomarker 
defined-subset individually. More precisely, if the sample size is calculated for the overall analysis 
and the proportion of the biomarker-defined subpopulation which responds to the novel treatment 
is very small, the statistical power for the subgroup analysis may be inadequate. In addition, when 
several biomarker-defined subpopulations and treatments are to be investigated, this strategy is not 
easy to be implemented. 
For the case of binary outcomes, Eng, 2014 [92] provided the formula for the required sample 
size to power the biomarker-positive and biomarker-negative patients separately. It is assumed that 
𝑌 is a binary variable which corresponds to a patient’s response to their randomly tailored treatment 
and 𝑃(𝑌|𝑇𝑟𝑡 = 𝑖, 𝑀 = 𝑗) = 𝑟𝑖𝑗 where 𝑖 corresponds to either the experimental or control treatment 
and 𝑗  corresponds to either the biomarker-positive patients or the biomarker-negative patients. 
Hence, 
𝑟𝑖𝑗 = 𝛽0 + 𝛽𝐴𝐼(𝑇𝑟𝑡 = 𝐴) + 𝛽+𝐼(𝑀 = 𝑀
+) + 𝛽𝐼𝐼(𝑇𝑟𝑡 = 𝐴, 𝑀 = 𝑀
+), (19) 
where 𝛽0 denotes a baseline effect, 𝛽𝐴 denotes the added effect of the experimental treatment, 𝛽+ 
denotes the biomarker-positive effect and 𝛽𝐼  denotes the nonadditive effect. Consequently, the 
proposed formula for the required sample size can be given by 
𝑵𝒔𝒕𝒓𝒂𝒕𝒊𝒇𝒊𝒆𝒅 = 2(𝑧𝑎 + 𝑧1−𝛽)
2
{
𝑟𝐴+(1 − 𝑟𝐴+) + 𝑟𝐵+(1 − 𝑟𝐵+)
(𝛽𝐴 + 𝛽𝐼)2
+
𝑟𝐴−(1 − 𝑟𝐴−) + 𝑟𝐵−(1 − 𝑟𝐵−)
(𝛽𝐴)2
}, (20) 
where 𝛼  correspond to the target level, 1 − 𝛽  corresponds to the power. Also, 𝑟𝐴+, 𝑟𝐵+  are the 
assumed response rates of biomarker-positive patients receiving the experimental and the control 
treatment respectively. Additionally, 𝑟𝐴−, 𝑟𝐵− are the assumed response rates of biomarker-negative 
patients receiving the experimental and the control treatment respectively. 
Mandrekar and Sargent, 2009 [31] provide a formula to calculate the required number of events 
when the trial has a survival outcome with 1:1 randomization to treatment arms, i.e., 
𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 =
4(𝑧𝑎/2 + 𝑧𝛽)
2
[log (
𝑚𝐴+
𝑚𝐵+
)]
2 +
4(𝑧𝑎/2 + 𝑧𝛽)
2
[log (
𝑚𝐴−
𝑚𝐵−
)]
2 , (21) 
  
 
where 𝑚𝐴+, 𝑚𝐴−, 𝑚𝐵+, 𝑚𝐵− , indicate the median overall survival for biomarker-positive and 
biomarker-negative patients receiving control and experimental treatment, respectively and 
𝜃1 =
𝑚𝐴+
𝑚𝐵+
= 𝐻𝑅𝑏𝑖𝑜𝑚+ , (22) 
𝜃2 =
𝑚𝐴−
𝑚𝐵−
= 𝐻𝑅𝑏𝑖𝑜𝑚− , (23) 
correspond to the hazard ratios of biomarker-positive and biomarker-negative subgroups and 
𝑧𝛼/2, 𝑧𝛽 denote the upper 𝛼/2- and upper 𝛽-points respectively of a standard normal distribution 
where 𝛼 and 𝛽 denote the assumed type I error and type II error respectively. More precisely, the 
total number of events is the sum of the required number of events for the biomarker-negative and 
biomarker-positive subpopulation. Freidlin et al., 2010 [61] stated that the required number of events 
in order to compare the experimental to the control treatment among the biomarker-positive patients 
for detecting a given effect size in this biomarker-positive subpopulation is identical to the number 
of events needed by an enrichment design (i.e., 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡). 
Another potential formula for the required total number of events when 1:1 randomization to 
treatment arms is assumed is given by 
𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 =
4(𝑧𝑎/2 + 𝑧𝛽)
2
[𝑘log(𝜃1) + (1 − 𝑘)log(𝜃2)]2
. (24) 
Although the formula proposed by Mandrekar and Sargent, 2009 [31] achieves a specific power 
(1 − 𝛽) for each biomarker-defined subgroup separately, the aforementioned formula proposed in 
the book of Harrington,, 2012 [114] aims to reach a power (1 − 𝛽)  for the overall population. 
According to Harrington,  2012 the required total number of patients to be entered to a stratified trial 
can be given by 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 =
4(𝑧𝑎/2 + 𝑧𝛽)
2
{
[𝑘𝑃𝑟(+)(𝑒𝑣𝑒𝑛𝑡)log(𝜃1) + (1 − 𝑘)𝑃𝑟(−)(𝑒𝑣𝑒𝑛𝑡)log(𝜃2)]
√𝑘𝑃𝑟(+)(𝑒𝑣𝑒𝑛𝑡) + (1 − 𝑘)𝑃𝑟(−)(𝑒𝑣𝑒𝑛𝑡)
}
, 
(25) 
where 𝑃𝑟(+)(𝑒𝑣𝑒𝑛𝑡), 𝑃𝑟(−)(𝑒𝑣𝑒𝑛𝑡) are the probability of an event in biomarker-positive subset and 
biomarker-negative subset respectively. If we divide the required total number of events for the 
enrichment design by the aforementioned formula for the required total number of events for the 
stratified design, we can get the following approximation of the ratio 
𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
=
[log(𝜃1)]
2
[𝑘log(𝜃1) + (1 − 𝑘)log(𝜃2)]2
=
1
[𝑘 + (1 − 𝑘)
log(𝜃2)
log(𝜃1)
]
2. (26) 
Further, Zhao and Simon [19,28,53,57,60] have developed an online tool for the calculation of 
sample size for biomarker stratified randomized designs with binary or time-to-event endpoints 
which is available online at the following web site http://brb.nci.nih.gov/brb/samplesize/sdpap.html 
[115]. More precisely, the sample size for both binary and time-to-event endpoints can be performed 
with three different analysis plans; A, B and C. Before choosing one of these analysis plans in the web 
site, for binary endpoints we need to specify the probability of treatment response in the control arm 
as well as the proportion of biomarker-positive patients. For survival endpoints, the hazard ratio of 
biomarker-positive patients versus the biomarker-negative control patients which corresponds to the 
hazard ratio of prognostic effect as well as the proportion of biomarker-positive patients must be 
specified. 
Analysis plan A is performed when there is confidence that an overall treatment effect exists. It 
determines the sample size on the basis of first of all comparing the experimental treatment to the 
control treatment in the entire randomized population at a reduced two-sided significance level  
𝑎 < 0.05. If the overall test is not significant, then the experimental treatment is compared to the 
control treatment in the biomarker-positive patients using the type I error 𝑎 = 0.05. Analysis Plan A 
  
 
is similar to the ‘Biomarker-positive and overall strategies design’ with fall-back analysis described 
later in this paper; the difference lies in this in terms of the significance levels they have used. In order 
for the sample size to be estimated, the anticipated overall effect estimate, reduced two-sided 
significance level and power for the overall test need to be specified. 
Analysis plan B is performed when there is confidence that there is a treatment effect in the 
biomarker-positive subpopulation. It determines the sample size on the basis of first of all comparing 
the experimental treatment to the control treatment in the biomarker-positive subgroup at a two-
sided significance level of 𝑎 = 0.05 level. If the treatment effect is found to be significant at this 0.05 
level, then treatment effect is evaluated in the biomarker-negative subgroup again at a two-sided 
significance level of 0.05 level. This analysis plan is identical to the ‘Sequential subgroup specific 
design’ described later in this paper. In order for the sample size to be estimated, apart from the fixed 
significance level set to 0.05, the anticipated effect estimate in the biomarker-positive subpopulation 
and power need to be specified. 
Analysis plan C first tests whether there is a statistically significant interaction between 
treatment and biomarker [60] at a significance level 𝑎 ≤ 0.05. If the interaction is not significant, then 
the treatments are compared in the overall study population at a two-sided significance level 0.05. 
Otherwise, the treatments are compared within the two biomarker subgroups separately at a two-
sided 0.05 significance level for each subgroup. Analysis Plan C follows either the ‘marker-by-
treatment interaction process with interaction or the separate test process’ described above. In order 
for the sample size to be estimated, the anticipated treatment effect in the overall study population, 
the one-sided significance level for interaction test and the power for testing the treatment effect in 
the overall population need to be specified. 
In marker stratified designs, three designs can be included which differ in terms of their 
statistical testing strategies, i.e., (i) Subgroup-specific designs (i.e., sequential subgroup-specific 
design, parallel subgroup-specific design); (ii) Biomarker-positive and overall strategies (i.e., 
biomarker-positive and overall strategies with parallel assessment, biomarker-positive and overall 
strategies with sequential assessment, biomarker-positive and overall strategies with fall-back 
analysis); (iii) Marker sequential test design (MaST) and they are discussed in the following sections. 
Statistical considerations: Despite the fact that the marker stratified designs allow testing the 
treatment effect not only in the entire population but also in each biomarker-defined subpopulation, 
they might not be feasible when the prevalence of biomarker is low. Another limitation of such 
designs is that they might require a large sample size where several treatments and biomarkers are 
investigated in the study. 
Subgroup-Specific designs: This strategy is an approach to analyze a biomarker-stratified trial. 
It is composed of two types; ‘Sequential Subgroup-Specific design’ and ‘Parallel Subgroup Specific 
design’. Both biomarker-positive and biomarker-negative subgroups can be tested in a sequential or 
in a parallel way. With the parallel way, we can assess simultaneously both biomarker-positive and 
biomarker-negative patients, whereas, with the sequential way we perform first the assessment of 
biomarker-positive patients and if the result is positive then we continue with the biomarker-negative 
patients. 
Sequential Subgroup-Specific design: This approach was referred to in 11 papers (11%) of our 
review. Figure 5 graphically represents this approach. 
  
 
 
Figure 5. Sequential Subgroup-Specific design. “R” refers to randomization of patients. Uncolored 
boxes are referred to the first stage of the trial and colored boxes are referred to the second stage of 
the trial. 
Design: The sequential testing procedure uses the assumption that it is unlikely that the new 
treatment will be effective in the biomarker-negative patients unless it is effective in the biomarker-
positive patients. First treatment effect is tested in the biomarker-positive subpopulation using the 
overall two-sided significance level 𝛼 = 0.05 (Type I error); if this test is significant then treatment 
effect is tested in the biomarker-negative subgroup using the same level of significance 𝛼. 
Utility: Its use is recommended when there is compelling evidence that biomarker-positive 
individuals benefit more from the experimental treatment than the biomarker-negative patients. 
More precisely, it is appropriate when it is not expected for the novel treatment to be effective in 
biomarker-negative patients unless it is beneficial for the biomarker-positive patients. 
Methodology: As this subgroup-specific design follows a sequential assessment and thus the 
design is composed of two stages, the sample size calculation is also staged. For binary outcome the 
required number of biomarker-positive patients is the same as for the enrichment design, i.e., 
𝑁𝑆𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
+ = 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 (27) 
As Simon, 2008 [60] stated, the total number of patients will be approximately  
𝑁𝑆𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 =
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
𝑘
 (28) 
where 𝑘 is the proportion of biomarker-positive patients and the number of biomarker-negative 
patients will be approximately 
𝑁𝑆𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
− =
(1 − 𝑘)𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
𝑘
. (29) 
For the conduct of this design, it is important to ensure that there is also an adequate number of 
biomarker-negative patients for analysis purposes. For time-to-event outcomes, the required number 
of events for biomarker-positive patients is the same with the required number of events in the 
enrichment design, i.e.,  
  
 
𝐷𝑆𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
+ = 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 . (30) 
At the time that there are 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 patients, the required number of events among biomarker-
negative patients in terms of that among biomarker-positive patients (𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡) is given by 
𝐷𝑆𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
− = 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 (
𝜆−
𝜆+
) (
1 − 𝑘
𝑘
), (31) 
where 𝜆−, 𝜆+ are the event rates in biomarker-negative and biomarker-positive control subsets 
at the time when there are 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 events in the biomarker-positive subgroup [60]. 
The significance levels 𝑎 can also be considered as one-sided significance levels in situations 
where our alternative hypothesis is not that there is just a treatment effect but that the treatment 
benefit in the experimental group is greater than that of the control group. 
Statistical considerations: This strategy preserves the overall type I error rate 𝑎 but requires a 
smaller number of positive patients as compared to the second type of subgroup-specific design, the 
so-called parallel subgroup-specific design (see below). Furthermore, it enables the identification of 
treatment efficacy in the biomarker-positive and biomarker-negative subpopulations separately. 
However, it yields low power when there is homogeneity of treatment effect across the different 
biomarker-defined subpopulations. Furthermore, in case that test for treatment effect among 
biomarker-negative patients is not statistically significant, an “exploratory” analysis on the 
biomarker-negative subgroup might be considered. 
Parallel Subgroup-Specific design: This design was identified in three papers (3%) of our 
review. 
Design: Parallel subgroup-specific design (Phase III), also referred to as a Phase III Biomarker-
Stratified design evaluates treatment effects separately in the positive biomarker-defined subgroup 
and in the negative biomarker-defined subgroup simultaneously. A graphical illustration of this 
strategy is given in Figure 6. 
 
Figure 6. Parallel Subgroup-Specific design. “R” refers to randomization of patients. 
  
 
Utility: It is appropriate when the aim of the study is to give treatment recommendations for 
each biomarker-defined subgroup separately at the same time. 
Methodology: In order to control the overall type I error rate of the design at the overall level of 
significance 𝛼  (Type I error) it is required to allocate this overall 𝛼  between the test for the 
biomarker-positive subgroup and the test for the biomarker-negative subgroup using the Bonferroni 
correction method [124] for multiple testing; e.g., if we choose the value of 0.025 for the global 
significance level 𝛼, then we could choose the values of 𝑎1 = 0.010 and 𝑎2 = 0.015 for testing the 
biomarker-negative and biomarker-positive subgroups respectively. This trial design is powered in 
such a way so as to detect the treatment effect in each biomarker-defined subgroup separately. A 
higher portion of the type I error rate can be given for the test within the biomarker-positive subgroup 
in order to maximize the power of the trial to identify the treatment effect in this subpopulation. 
However, even if there is a slight increase in the type I error probability spent on the test of one of 
the biomarker-defined subgroups, the power would probably not change much. 
As in the sequential subgroup-specific design, the probability of rejecting either the null 
hypothesis of no treatment effect in the biomarker-positive subset or in the biomarker-negative effect 
under the global null hypothesis is less than or equal to the overall type I error rate 𝑎. Additionally, 
the probability of rejecting the null hypothesis of no treatment effect in the biomarker-negative 
subpopulation when the treatment benefit is only restricted to biomarker-positive patients is less than 
or equal to 𝑎. The significance levels 𝑎 can be considered as one-sided or two-sided significance 
levels.  
Statistical considerations: With this approach, in case that the overall level of significance 𝑎 is 
equal in both subgroup-specific designs, it is more difficult to achieve statistical significance in the 
biomarker-positive subgroup as compared to the sequential subgroup-specific design due to the 
allocation of the overall significance level between the two biomarker-defined subgroup tests. 
Biomarker-positive and overall strategies: This design provides an alternative strategy to 
analysing a biomarker-stratified design. It is an indirect way of evaluating both biomarker and 
treatment by testing the treatment effect in the entire study population and in the biomarker-positive 
subgroup separately. Three approaches are included in the biomarker-positive and overall strategies; 
the parallel assessment, the sequential assessment and the fall-back design (see below). 
Despite the fact that the biomarker-positive subgroup and overall strategy design allows the 
treatment effect to be tested in the biomarker-positive subpopulation and provides good statistical 
power when the treatment effect is homogeneous across subgroups, this design is usually considered 
problematic and its use is not often recommended. More precisely, a major concern is that when the 
benefit of the novel treatment is limited to the biomarker-positive patients, it is possible that the 
design might lead to a wrong recommendation of treatment for the biomarker-negative patients. This 
might happen because when there is no treatment effect in the biomarker-negative subgroup, there 
might be an observed effect in the entire population due to the potentially large effect in the 
biomarker-positive patients. This concern is particularly pronounced in the sequential version of the 
design, which first tests the biomarker-positive subgroup and then, if it is positive, it tests the overall 
population. 
Biomarker-positive and overall strategies with parallel assessment: This approach was 
identified in eight papers (8%) of our review. Figure 7 graphically represents this strategy. In the 
parallel version, we test both the overall population and biomarker-positive subgroup 
simultaneously. 
  
 
 
Figure 7. Biomarker-positive and overall strategies with parallel assessment. “R” refers to 
randomization of patients. 
Design: In this approach the treatment effect is tested in both the entire study population and in 
the biomarker-positive patients while controlling the type I error by allocating the overall significance 
level 𝛼 between the two tests. The significance level 𝑎 can be considered as one-sided or two-sided. 
Utility: The parallel version is recommended when the aim of the study is to assess the treatment 
effect in both the overall study population and in the biomarker-positive subgroup but not in the 
biomarker-negative subgroup. 
Methodology: If there is significant confidence that the biomarker is predictive, the sample size 
estimation is aimed at having a sufficient number of biomarker-positive individuals to enable the 
treatment effect in the biomarker positive subgroup to be detected. On the other hand, if there is no 
confidence in the predictive value of the biomarker, the sample size estimation is aimed at having a 
sufficient number of patients to detect a treatment effect in the overall study population [14]. 
Statistical considerations: This design has the ability to control the probability of rejecting the 
null hypothesis of no treatment effect either in the biomarker-positive population or in the biomarker-
negative population under the global null hypothesis of no treatment effect in the entire population 
at the overall significance level 𝑎. However, it cannot control the probability of rejecting the null 
hypothesis of no treatment effect in the biomarker-negative subset when the treatment benefit is 
restricted to biomarker-positive patients. Consequently, there is high risk of inappropriately 
recommending the experimental treatment for biomarker-negative patients. 
When the experimental treatment is compared to the control treatment within the overall 
population and the overall treatment effect is significant, then the test has high statistical power. If 
we are testing only the biomarker-positive subgroup and the treatment effect in this subgroup is 
  
 
significant, the statistical power is again high. This prospective subset analysis plan is based on 
testing both the overall study population and the biomarker-positive subgroup using significance 
levels, which are chosen in such a way that the overall significance level is equal or less than 𝑎 (type 
I error). An easy way is to split 𝑎 in such a way that the significance level for the entire population 
and the significance level for the biomarker-positive subset equals to overall significance level 𝑎 
(typically 𝑎 = 0.05 ). For example, the SATURN trial (NCT00556712) [96] which employs a 
prospective subset strategy used the value of 0.03 as level of significance to test the treatment effect 
in the entire population and the value of 0.02 to test the treatment effect in the biomarker-positive 
subset; therefore, the overall level of significance was preserved at 0.05. The approach can be overly 
conservative as in the SATURN trial because of the correlation between the global and subgroup test. 
Other approaches [98,125-128] have been proposed for adjusting the level of significance of both tests 
in a more accurate and less conservative way. 
Biomarker-positive and overall strategies with sequential assessment: This approach was 
referred to in 11 papers (11%) of our review. A graphical illustration of this approach is shown in 
Figure 8. 
 
Figure 8. Biomarker-positive and overall strategies with sequential assessment. “R” refers to 
randomization of patients. Uncolored boxes are referred to the first stage of the trial and colored boxes 
are referred to the second stage of the trial. 
Design: In this sequential version of the biomarker-positive and overall strategies, we first test 
the biomarker-positive subgroup using the significance level 𝛼; if the test is significant, then we test 
  
 
the treatment effect in the overall population using the same 𝛼 level. The significance levels 𝑎 can 
be considered as one-sided or two-sided significance levels. 
Utility: The sequential version might be useful in cases where the experimental treatment is 
expected to be effective in the overall study population.  
Methodology: As this design comprises two sequential stages, it follows that the sample size 
calculation should also be staged. At the first stage, the standard formula for a traditional randomized 
trial can be used for the biomarker-positive subgroup using the significance level 𝛼 to estimate the 
treatment effect in that subset. More precisely, the formula used in the enrichment design for the 
required total number of events or the required number of patients can be used at the first stage of 
this design. At the second stage, the sample size must be adjusted in order to yield appropriate power 
for the entire population. 
Statistical considerations: As in the parallel version of this designs, this strategy does not allow 
for identification of treatment efficacy in the biomarker-negative subgroup and despite the fact that 
it can control the overall type I error 𝛼  it cannot control the probability of rejecting the null 
hypothesis of no treatment effect in the biomarker-negative subset when the treatment benefit is 
restricted to biomarker-positive patients. Consequently, for this design also there is high risk of 
inappropriately recommending the novel treatment for biomarker-negative patients. 
Biomarker-positive and overall strategies with fall-back analysis: This strategy was identified 
in 15 papers (15%) of our review. It evaluates both the treatment effect in the overall study population 
and in the biomarker-positive subgroup sequentially. Figure 9 graphically represents this strategy. 
 
Figure 9. Biomarker-positive and overall strategies with fall-back analysis. “R” refers to 
randomization of patients. Uncolored boxes are referred to the first stage of the trial and colored boxes 
are referred to the second stage of the trial. 
  
 
Design: In the fall-back design, we first test the overall population using the reduced 
significance level 𝑎1 and if the test is significant, we consider that the novel treatment is effective in 
the overall population; however, if the result is not significant then we test the treatment effect in the 
biomarker-positive subgroup using the level of significance 𝑎2 = 𝑎 − 𝑎1 , where 𝑎  is the overall 
significance level (Type I error rate). The significance levels 𝑎 can be considered as one-sided or two-
sided significance levels. The same analysis plan was used in the adaptive signature design which is 
further described in our methodological review regarding the biomarker-guided adaptive designs, 
Antoniou et al., 2016 [35]. More precisely, the difference between the adaptive signature design and 
the fall-back design is the following: in the adaptive signature design, in case that the first stage 
failures to show treatment effectiveness in the entire population, then the study population is divided 
in order to develop and validate a biomarker, using a split sample strategy, whereas in the biomarker-
positive and overall strategies design with fall-back analysis the biomarker assessment is conducted 
at the beginning of the trial. However, both of the designs test at the first stage the entire population 
at the significance level 𝑎1 and at the second stage the biomarker-positive patients at the significance 
level 𝑎2 = 𝑎 − 𝑎1. 
Utility: This approach is recommended when there is insufficient confidence in the predictive 
value of the biomarker and that the novel treatment is believed to be effective in all individuals (i.e., 
the rationale for the biomarker is weak). This design can be used in order to avoid the possibility of 
missing an important treatment effect in the biomarker-positive patients (with insufficient benefit in 
the biomarker-negative subgroup).  
Methodology: The sample size should be set in such a way so as to yield adequate power for 
the overall test at the reduced significance level 𝑎1 and for the potential biomarker positive subgroup 
analysis at significance level 𝑎 − 𝑎1 [60]. The fall-back version is identical to the parallel version of 
biomarker-positive and overall strategies in terms of sample sizes and study outcomes, however the 
difference between these approaches is that the fall-back strategy is useful in settings where a 
biomarker will be assessed only if the overall population benefit is not promising [14]. This strategy 
can test the treatment effectiveness in biomarker-positive patients even if there is no detected benefit 
of the novel treatment in the overall population. However, it does not evaluate clearly the treatment 
benefit in the biomarker-negative subpopulation. 
Statistical considerations: As the two aforementioned biomarker-positive and overall designs, 
this strategy can again control the overall type I error 𝛼 but it cannot control the probability of 
rejecting the null hypothesis of no treatment effect in the biomarker-negative subgroup when the 
treatment benefit is restricted to biomarker-positive patients. Consequently, there is high risk of 
inappropriately recommending the novel treatment for biomarker-negative patients. Song et al., 2007 
[129] and George, 2008 [1] have discussed refinement of the significance levels associated with this 
design, which takes into account the correlation between the test for overall treatment effect and the 
test for the biomarker-positive treatment effect [60]. Additionally, a recent paper by Choai et al., 2015 
[97] proposes a bias-corrected estimation method for treatment effects for the all-comers randomized 
clinical trials with a predictive biomarker which incorporate the fall-back analysis. For Choai et al., 
2015 [97] the terminology “all-comers randomized clinical trials” is referred to the “Biomarker-
positive and overall strategies with fall-back analysis”. More precisely, as this study design has an 
adaptive nature and is composed of two stages, a bias is possible to arise in the treatment effect 
estimation in the biomarker-positive subset when the first stage of the trial yields an overall result 
which is not significant and thus fails to demonstrate a treatment efficacy in the entire population. 
For this reason, Choai et al. ,2015 [97], formulate a bias function using polynomials in order to take 
into account the possibility of failing to demonstrate overall treatment efficacy during the first stage 
of the trial. 
Marker Sequential test design (MaST): This design was identified in four papers (4%) of our 
review and while controlling the appropriate type I error rates, it evaluates not only the biomarker-
positive and biomarker-negative subgroups but also the entire population sequentially to limit the 
assessment of treatment effect in the overall population when it seems that the biomarker-positive 
  
 
subgroup does not benefit from the novel treatment. A graphical illustration of this approach is given 
in Figure 10. 
 
Figure 10. Marker Sequential test design (MaST). “R” refers to randomization of patients. Uncolored 
boxes are referred to the first stage of the trial and colored boxes are referred to the second stage of 
the trial. 
Design: In this design which owns an adaptive nature, first, the biomarker-positive subgroup is 
tested at a reduced level 𝑎1  in [0, 𝑎] and if the result is significant, then the biomarker-negative 
subgroup is tested at the global significance level 𝛼. Otherwise, if the result is not significant, then 
the overall population is tested at level 𝑎2 = 𝑎 − 𝑎1  in order to make a treatment recommendation 
for the biomarker-negative patients. 
Utility: It is generally recommended when robust evidence is available regarding a biomarker 
and there is prior evidence showing that the novel treatment is more beneficial for the biomarker-
positive patients as compared to the biomarker-negative patients. Additionally, it is appropriate 
when we can assume that the treatment will not be beneficial for the biomarker-negative subgroup 
unless it is effective for the biomarker-positive subgroup. Additionally, the marker sequential test 
design is considered as an alternative to the sequential subgroup-specific design when the aim is to 
consider the treatment effect not only in biomarker-positive but also in the biomarker-negative 
patients. 
Methodology: Freidlin et al., 2014 [69] recommended using the value of 0.022 for the reduced 
significance level 𝑎1 in order to control the type I error rate for biomarker-negative patients at the 
global significance level 𝛼 = 0.025 and the value of 0.04 for the reduced significance level 𝑎1  in 
order to control the type I error rate for biomarker-negative patients at the global significance level 
𝛼 = 0.05. 
Regarding the sample size for such a design where there is prior evidence indicating strong 
predictive ability of the biomarker, a standard sample size calculation (i.e., the same sample size 
calculation as for the enrichment designs) can be used for biomarker-positive subpopulation or 
  
 
alternatively, researchers can use the sample size calculation used for the sequential subgroup-
specific design. However, in order to have sufficient number of biomarker-positive patients to detect 
treatment effectiveness in that particular biomarker-defined subset and consequently to reach the 
desired power, the sample size should be calculated using the reduced level 𝑎1 [0, 𝑎] instead of the 
global significance level 𝛼  which is used in the sample size formulae of the enrichment and 
sequential subgroup-specific designs. This will result in a small increase in the number of patients as 
compared to the enrichment and sequential subgroup-specific designs. Otherwise, if the reduced 
significance level 𝑎1 is not used, this would yield minor loss of power. 
Statistical consideration: Freidlin et al., 2014 [69] performed a comparison between the MaST 
and the sequential subgroup-specific design through a simulation study and concluded that the 
marker sequential design yields higher power in cases where the treatment effect is homogeneous 
across biomarker-defined subgroups. Additionally, with this approach, the power is preserved in 
situations where the experimental treatment is effective only for the biomarker-positive patients. 
Furthermore, in situations where biomarker status is not available for a portion of patients included 
in the trial, the marker sequential test design can either exclude these patients or include them in the 
global test, whereas, the proposed subgroup-specific designs do not consider inclusion of these 
patients in the analyses. If researchers decide to exclude patients with unavailable biomarker status 
from the study when using a MaST design, no statistical adjustment is required. On the other hand, 
if the inclusion of this study population is chosen, then this can result in inflation of the type I error 
rate for the biomarker-negative subpopulation above the global significance level 𝛼  due to the 
modification of correlation structure between the biomarker-defined subgroup tests and global test. 
In addition, while both MaST and subgroup-specific designs have the ability to control the probability 
of incorrectly rejecting the null hypothesis of no treatment effect in the biomarker-negative patients 
at the significance level 𝛼 when the experimental treatment does not work in either biomarker-
defined subgroup, the sequential subgroup-specific approach typically has a smaller probability of 
incorrectly rejecting the null hypothesis of no treatment effect in the biomarker-negative subset 
(when the null hypothesis is true) as compared to the MaST design, especially under the global null 
hypothesis of no treatment effect in the entire population; the probability of incorrectly rejecting the 
null hypothesis of no treatment effect in the biomarker-negative patients depends on the choice of 
𝑎1 . This conservativeness of sequential subgroup-specific design, which is due to its sequential 
nature, makes the MaST design advantageous [69]. 
2.3.2. Hybrid Designs 
Hybrid designs (Phase III) were identified in 14 papers (14%) of our review and they can be 
included in the all-comers designs, where the entire population is firstly screened for biomarker 
status and all individuals enter the trial. A graphical illustration of this design is given in Figure 11. 
 
Figure 11. Hybrid design. “R” refers to randomization of patients. 
  
 
Design: In this approach, only the biomarker-positive patients are randomly assigned to either 
the experimental treatment group or to the control treatment group whereas the biomarker-negative 
patients receive the control treatment. These designs were first defined by Mandrekar and Sargent 
[30,31]. The difference compared with the enrichment designs is that the biomarker-negative patients 
are not excluded from the study.  
Utility: Hybrid designs can be used when there is compelling prior evidence which shows 
detrimental effect of the experimental treatment for a specific biomarker-defined subgroup (i.e., 
biomarker-negative subgroup) or some indication of its possible excessive toxicity in that subgroup, 
thus making it unethical to randomize the patients within this population to the experimental 
treatment. 
Methodology: Similar to the enrichment design, hybrid designs are powered to identify 
treatment effect only in the biomarker-defined subgroup which is randomly assigned to the 
experimental or control treatment groups. Consequently, the same formula used for the required 
number of patients or events for the enrichment designs can be used for hybrid designs. This design 
is a combination of an enrichment design where we randomize patients to either the experimental or 
the control treatment group and a single-arm design in biomarker-negative patients. 
Statistical considerations: The strength of the hybrid design is that apart from the evaluation of 
the predictive ability of a biomarker, the feasibility of a prognostic biomarker can also be tested. It 
can be considered as an advantageous design of the enrichment designs when there is prior evidence 
showing not only that the control treatment works well for the biomarker-negative population but 
also a detrimental effect of the experimental treatment for that subgroup or possible excessive toxicity 
as we do not exclude these patients from the trial as it happens in the enrichment designs. 
2.4. Biomarker-Strategy Designs 
Generally, with biomarker-strategy designs, the study population is randomized to treatment 
strategies as opposed to treatments per se. More precisely, patients are randomized to either a 
biomarker-based treatment strategy arm where the biomarker is used in deciding on approach to 
treatment, or to an arm that does not use the biomarker to guide treatment. Consequently, biomarker-
strategy designs make a comparison between two strategies—one which uses biomarker information 
to inform treatment approach and the other that does not. 
These designs are also known as biomarker-based strategy designs or signature-based strategy 
designs and they are composed of four subtypes; (i) biomarker-strategy designs with biomarker 
assessment in the control arm; (ii) biomarker-strategy designs without biomarker assessment in the 
control arm; (iii) biomarker-strategy designs with treatment randomization in the control arm and 
(iv) reverse marker-based strategy designs. Whilst patients randomized to the non-biomarker based 
strategy arm in the first two design subtypes are allocated the control treatment, in the third design 
subtype those patients undergo secondary randomization to either the control or experimental 
treatment. The fourth design subtype differs from the three aforementioned subtype designs as the 
non-biomarker based strategy arm is replaced by the reverse marker-strategy arm. The first and 
second types are similar with the difference being only in terms of ethical/feasibility issues regarding 
the acquisition of biomarker status at the beginning of the trial. 
This approach is preferred when the study is planned for a confirmatory phase of a certain 
biomarker-based strategy allowing for comparison between the biomarker-based strategy and non-
biomarker-based strategy. 
2.4.1. Biomarker-Strategy Design with Biomarker Assessment in the Control Arm 
This approach is described in 21 (21%) papers of our review.  
Design: First, the study population enrolled in the trial is tested for its marker status. Next, 
patients irrespective of their biomarker status are randomized either to the biomarker-based strategy 
arm (also referred to as personalized arm) or to the non-biomarker-based strategy arm. In the 
biomarker-based strategy arm, biomarker-positive patients receive the experimental treatment, 
whereas, biomarker-negative patients receive the control treatment. Patients who are randomized to 
  
 
the non-biomarker-based strategy arm receive the control treatment irrespective of their biomarker 
status. A graphical illustration of this design is given in Figure 12. This biomarker-strategy design 
can be extended to more than one experimental treatment. More precisely, this extension is referred 
to as Individual profile design in literature and was identified in two papers [36,72] (2%) of our 
review. This design includes different individual status, e.g., instead of biomarker-positive and 
biomarker-negative subgroups we can have patients who are positive for biomarker 1, biomarker 2, 
biomarker n, leading to the selection of personalized treatments, (patients who are positive for 
biomarker 1 are treated with the corresponding experimental treatment 1, etc.). 
 
Figure 12. Biomarker-strategy design with biomarker assessment in the control arm. “R” refers to 
randomization of patients. 
Utility: This approach is useful when we want to test the hypothesis that the treatment effect 
based on the biomarker-based strategy approach is superior to that of the standard of care. 
Methodology: The clinical utility of a biomarker can be evaluated by comparing the two strategy 
groups. The predictive utility of the marker-based treatment strategy could be assessed by comparing 
the outcome of all patients in the biomarker-based strategy arm to all patients in the non-biomarker-
based strategy arm. Patients in the marker-based strategy arm do not need to be limited to two 
treatments; in principle, a marker-based strategy involving many biomarkers and many possible 
treatments could be compared to standard of care treatment. 
According to Freidlin et al., 2010 [61], assuming a survival outcome, the required sample size in 
terms of number of events for this type of biomarker-strategy design in order to reach power (1 − 𝛽) 
at significance level 𝛼 (type I error) can be given by 
𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼 = 4 [
(z𝛼/2 + z𝛽)
𝑘 logθ1
]
2
, (32) 
where 𝑘 denotes the prevalence of biomarker-positive patients, θ < 1 denotes the assumed hazard 
ratio in the biomarker-positive subpopulation and 𝑧𝛼/2,  𝑧𝛽  denote the upper 𝛼/2- and upper 𝛽-
points respectively of a standard normal distribution where 𝛼 and 𝛽 denote the assumed type I 
error and type II error respectively. According to Freidlin et al.2010[61], it is assumed that there is no 
treatment effect in the biomarker-negative subpopulation (corresponding to a hazard ratio of 
experimental treatment versus control treatment of 1) and that there is no prognostic effect of the 
biomarker under the control treatment. Consequently, the overall hazard ratio between experimental 
and control arms in biomarker-positive patients and biomarker-negative patients can be 
approximated by exp[𝑘 logθ + (1 − 𝑘) log1] = θ𝑘 [61] and this is the reason why the formula which 
  
 
gives the required total number of events (𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦) contains only the hazard ratio of biomarker-
positive patients. Freidlin et al., 2010 [61] provided the aforementioned formula assuming that all 
random assignments use 1:1 randomization. 
Additionally, Young et al., 2010 [26] determined the total sample size needed for this type of 
biomarker-strategy designs when using continuous clinical endpoints by  
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼 =
2(𝑧1−𝛼/2 + 𝑧1−𝛽)
2
(𝜏𝑚
2 + 𝜏𝑛
2)
(𝑣𝑚 − 𝑣𝑛)2
, (33) 
where 𝑧1−𝛼/2, 𝑧1−𝛽  denote the lower 1 − 𝛼/2- and lower 1 − 𝛽-points respectively of a standard 
normal distribution, 𝛼 and 𝛽 denote the assumed type I error and type II error respectively, 𝑣𝑚 and 
𝑣𝑛 denote the mean response from the biomarker-based strategy arm and the non-biomarker-based 
strategy arm respectively, and 𝜏𝑚
2 ,  𝜏𝑛
2  denote the variance of response for the biomarker-based 
strategy arm and non-biomarker-based strategy arm respectively. Young et al., 2010 [26] also 
provided formulae for the aforementioned variances which depend on sensitivity and specificity of 
the assay, such that any error in the evaluation of biomarker in the biomarker-based strategy can be 
accounted for. 
For the case of binary outcomes, Eng, 2014 [92] provided the formula for the required sample 
size for each arm in a test of proportions between the two randomization arms (biomarker-based 
strategy arm and non-biomarker-based strategy arm). This formula can be given by 
𝑵𝒔𝒕𝒓𝒂𝒕𝒆𝒈𝒚 𝑰/𝒂𝒓𝒎 =
(𝑧𝑎 + 𝑧1−𝛽)
2
[𝑔1(1 − 𝑔1) + 𝑔2(1 − 𝑔2)]
Δ2
2  (34) 
where 𝛼  corresponds to the target level, 1 − 𝛽  corresponds to the power, 𝑔1  is the expected 
response rate in the biomarker-based strategy arm, 𝑔2  is the expected response rate in the non-
biomarker-based strategy arm and ∆2= 𝑔1 − 𝑔2. The expected response rates  𝑔1, 𝑔2 can be found by 
calculating the formulae 𝑘𝑟𝐴+ + (1 − 𝑘)𝑟𝐵−  and 𝑟𝐵  respectively, the prevalence of biomarker-
positive patients corresponds to 𝑘 and 𝑟𝐴+, 𝑟𝐵− are the assumed response rates of biomarker-positive 
patients receiving the experimental treatment and biomarker-negative patients receiving the control 
treatment, 𝑟𝐵 denotes the marginal effect of treatment B (control treatment). 
Statistical considerations: This type of designs is able to inform researchers whether the 
biomarker is prognostic, since both biomarker positive and negative patients are exposed to the 
control treatment, but it cannot answer the question of whether the biomarker is predictive since only 
biomarker positive patients are exposed to the experimental treatment. Additionally, these designs 
have been criticized by many authors as less efficient than the marker-stratified designs since it is 
possible for some patients in both the biomarker-based strategy arm and non-biomarker-based 
strategy arm to be assigned to the same treatment (due to the existence of biomarker-negative patients 
in both strategy arms the treatment effect can be diluted) and they require a large sample size to 
detect an overall difference in outcomes between arms. Furthermore, these designs cannot compare 
experimental treatment to control treatment directly as they are designed to compare not the 
treatments but the biomarker-strategies. Another limitation of these designs is the uncertainty about 
whether the results which indicate efficacy of the biomarker-directed approach to treatment are 
caused due to a true effect of the biomarker or due to a treatment effect irrespective of the biomarker 
status. 
2.4.2. Biomarker-Strategy Design without Biomarker Assessment in the Control Arm 
This strategy was identified in 14 papers (14%) of our review. 
Design: In this approach, patients are again randomized between testing strategies (i.e., 
biomarker-based strategy and non-biomarker-based strategy) but it differs in terms of the timing of 
biomarker evaluation. More precisely, first, patients are randomized to either the biomarker-based 
strategy or to the non-biomarker-based strategy. Next, this design evaluates the biomarkers only in 
patients who are assigned to the biomarker-based strategy. Patients who are found to be biomarker-
positive will receive the experimental treatment and patients who are biomarker-negative will 
  
 
receive the control treatment. On the other hand, the population which is randomized to the non-
biomarker-based strategy will receive the control treatment. A graphical illustration of this design is 
given in Figure 13. 
 
Figure 13. Biomarker-strategy design without biomarker assessment in the control arm. “R” refers to 
randomization of patients. 
Utility: This design is useful in situations where it is either not feasible or ethical to test the 
biomarker in the entire population due to several logistical (e.g., specimens not submitted), technical 
(e.g., assay failure) or clinical reasons (e.g., tumor inaccessible); thus the biomarker status is obtained 
only in patients who are tailored to the biomarker-based strategy arm. 
Methodology: The same mathematical formula for sample size calculation assuming a 
continuous clinical outcome proposed by Young et al. (2010) [26] and the formula assuming binary 
outcome proposed by Eng, 2014 [92] for the biomarker-strategy design with biomarker assessment in 
the control arm could be applied. Further, in terms of survival outcome, the same formula provided 
for the required number of events in the first version of biomarker-strategy designs (i.e., biomarker-
strategy design with biomarker assessment in the control arm) could be considered. 
Statistical considerations: These designs have the same advantages and limitations as the 
previously discussed biomarker-strategy design with biomarker assessment in the control arm, e.g., 
they have been criticized for their lack of efficiency due to the fact that biomarker negative patients 
are exposed to the control treatment in both arms of the trial. An additional limitation is that the 
biomarker-positive and biomarker-negative subpopulations might be more imbalanced as compared 
with the first type of biomarker-strategy design due to the fact that the randomization is performed 
before the evaluation of biomarker (balancing the randomization is useful to ensure that all 
randomized patients have tissue available). 
2.4.3. Biomarker-Strategy Design with Treatment Randomization in the Control Arm 
Sargent and Allegra [108] proposed another version of Biomarker-strategy designs where there 
is a second randomization between experimental and control treatment in the non-biomarker guided 
strategy arm. This strategy is referred to in 17 papers (17%) of our review. 
Design: A graphical illustration of this approach is given in Figure 14. The two previously 
described biomarker-strategy designs can answer the question about whether the biomarker-based 
strategy is more effective than standard treatment, irrespective of the biomarker status of the study 
population, whereas the biomarker-strategy design with treatment randomization in the control 
treatment is able to inform us about whether the biomarker-based strategy is better than not only the 
  
 
standard treatment but also better than the experimental treatment in the overall population. This is 
achieved by using a second randomization the ratio of which should be informed by the prevalence 
of the biomarker in question in the population as a whole to ensure balance between the study arms. 
Patients are first randomly assigned to either the biomarker-based strategy arm or to the non-
biomarker-based strategy arm. Next, patients who are allocated to the non-biomarker-based strategy 
are again randomized either to the experimental treatment arm or to the standard treatment arm 
irrespective of their biomarker status. Patients who are allocated to the biomarker-based strategy and 
who are biomarker-positive are given the experimental treatment and patients who are biomarker-
negative are given the control treatment. The clinical utility of the biomarker is evaluated by 
comparing treatment effect between the biomarker-based strategy arm and non-biomarker-based 
strategy arm. Such an approach can also identify whether a novel treatment is more effective in the 
entire population or in a biomarker-defined subgroup only, since both biomarker subgroups are 
exposed to both treatments. 
 
Figure 14. Biomarker-strategy design with treatment randomization in the control arm. “R” refers to 
randomization of patients. 
Utility: These designs are preferable as compared to the two previously discussed biomarker-
strategy designs in cases where there is interest in whether the biomarker is not only prognostic but 
also predictive. 
Methodology: Mandrekar and Sargent, 2009 [31] calculated the total required sample size in 
terms of number of events for the comparison of a survival outcome in the biomarker-based strategy 
versus the non-biomarker-based strategy. According to them, the required total number of events 
when using 1:1 randomization to treatment arms is given by 
𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼 =
4(𝑧𝑎/2 + 𝑧𝛽)
2
{log [
2𝑘𝑚𝐵+ + 2(1 − 𝑘)𝑚𝐴−
𝑘(𝑚𝐴++𝑚𝐵+) + (1 − 𝑘)(𝑚𝐴−+𝑚𝐵−)
]}
2, (35) 
where 𝜅 denotes the prevalence of the biomarker-positive patients, 𝑚𝐴+, 𝑚𝐴−, 𝑚𝐵+, 𝑚𝐵−, denote the 
median survival for biomarker-positive and biomarker-negative patients receiving control and 
experimental treatments respectively. Also, the constants 𝑧𝛼/2,  𝑧𝛽 denote the upper 𝛼/2- and upper 
𝛽-points respectively of a standard normal distribution where 𝛼 and 𝛽 denote the assumed type I 
error and type II error respectively. 
Additionally, Young et al., 2010 [26], considering continuous clinical outcomes, calculated the 
total sample size by 
  
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼 =
2(𝑧1−𝛼/2 + 𝑧1−𝛽)
2
(𝜏𝑚
2 + 𝜏𝑛𝑟
2 )
(𝑣𝑚 − 𝑣𝑛𝑟)2
, (36) 
where 𝑧1−𝛼/2, 𝑧1−𝛽  denote the lower 1 − 𝛼/2- and lower 1 − 𝛽-points respectively of a standard 
normal distribution, 𝛼 and 𝛽 denote the assumed type I error and type II error respectively, 𝑣𝑚 and 
𝑣𝑛𝑟  denote the mean response from the biomarker-based strategy arm and the non-biomarker-based 
strategy arm,) and 𝜏𝑚
2 ,  𝜏𝑛𝑟
2  denote the variance of response for the biomarker-based strategy arm and 
non-biomarker-based strategy arm respectively. The only differences in the mathematical formula 
for the total sample size 𝑛𝑡 between this type of biomarker-strategy design and the first and second 
types mentioned above are the values of 𝑣𝑛𝑟  and  𝜏𝑛𝑟
2  , to reflect the fact that in the non-biomarker-
based strategy arm patients are randomly assigned to either the experimental or control treatment. 
Again, the formulae can be adjusted to account for uncertainty in biomarker assessment. 
For the case of binary outcomes, Eng, 2014 [92] provided the formula for the required sample 
size for each arm in a test of proportions between the two randomization arms (biomarker-based 
strategy arm and non-biomarker-based strategy arm). This formula can be given by 
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼/𝑎𝑟𝑚 =
(𝑧𝑎 + 𝑧1−𝛽)
2
[𝑔1(1 − 𝑔1) + 𝑔3(1 − 𝑔3)]
Δ3
2  (37) 
where 𝛼  correspond to the target level, 1 − 𝛽  corresponds to the power, 𝑔1  is the expected 
response rate in the biomarker-based strategy arm, 𝑔3  is the expected response rate in the non 
biomarker-based strategy arm and ∆3= 𝑔1 − 𝑔3. The expected response rates  𝑔1, 𝑔3  can be found by 
calculating the formulae 𝑘𝑟𝐴+ + (1 − 𝑘)𝑟𝐵−  and 𝑟𝐴 2⁄ + 𝑟𝐵 2⁄  respectively, 𝑟𝐴  and 𝑟𝐵  denote the 
marginal effect of treatment A (experimental treatment) and treatment B (control treatment) 
respectively. 𝑟𝐴+, 𝑟𝐵− are the assumed response rates of biomarker-positive patients receiving the 
experimental treatment and biomarker-negative patients receiving the control treatment. The 
prevalence of biomarker-positive patients corresponds to 𝑘. 
Statistical considerations: Similar to both aforementioned biomarker-strategy designs, the 
biomarker-strategy design with treatment randomization in the control arm will need larger sample 
size as compared to the marker-stratified designs. However, one strength is that they allow 
clarification of whether the results which indicate efficacy of the biomarker-directed approach to 
treatment are caused due to a true effect of the biomarker or due to a treatment effect irrespective of 
the biomarker status which does not happen in the first two types of biomarker-strategy designs. 
2.4.4. Reverse Marker-Based Strategy Design 
Eng, 2014 [92] proposed another version of biomarker-strategy designs where the non-
biomarker-based strategy arm which is included in the three aforementioned subtypes of biomarker-
strategy designs is replaced by the reverse marker-strategy arm. This strategy is referred to in four 
papers (4%) of our review. 
Design: A graphical illustration of this approach is given in Figure 15. In this design patients are 
randomized either to the biomarker-based strategy arm or the reverse biomarker-based strategy arm. 
As in the previous three biomarker-strategy subtype designs, patients who are allocated to the 
biomarker-strategy arm receive the experimental treatment if they are biomarker-positive whereas 
biomarker-negative patients receive the control treatment. By contrast, patients who are randomly 
assigned to the reverse biomarker-based strategy arm receive control treatment if they are biomarker-
positive, whereas biomarker-negative patients receive experimental treatment. 
  
 
 
Figure 15. Reverse Marker-Based strategy design. “R” refers to randomization of patients. 
Utility: Reverse marker-based strategy is a more efficient strategy as compared to the first and 
third biomarker-strategy subtype design for testing the interaction hypothesis of treatment and 
biomarker. This design should be used in cases where prior evidence indicates that both experimental 
and control treatment are effective in treating patients but the optimal strategy has not yet been 
identified. 
Methodology: This subtype design is balanced (i.e., the randomization frequencies for each 
treatment are equal independent of the prevalence of the biomarker) and it is powered to evaluate 
the interaction between treatment and biomarker. For the case of binary outcomes, Eng, 2014 [92] 
provided the formula for the required sample size for each arm in a test of proportions between the 
two randomization arms (biomarker-based strategy arm and reverse biomarker-based strategy arm). 
This formula can be given by 
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝑉/𝑎𝑟𝑚 =
(𝑧𝑎 + 𝑧1−𝛽)
2
[𝑔1(1 − 𝑔1) + 𝑔4(1 − 𝑔4)]
Δ4
2  (38) 
where 𝛼  correspond to the target level, 1 − 𝛽  corresponds to the power, 𝑔1  is the expected 
response rate in the biomarker-based strategy arm, 𝑔4 is the expected response rate in the reverse 
biomarker-based strategy arm and Δ4 = 𝑔1 − 𝑔4. The expected response rates 𝑔1, 𝑔4 can be found by 
calculating the formulae 𝑘𝑟𝐴+ + (1 − 𝑘)𝑟𝐵−  and 𝑘𝑟𝐵+ + (1 − 𝑘)𝑟𝐴−  respectively, 𝑟𝐴+, 𝑟𝐵−  are the 
assumed response rates of biomarker-positive patients receiving the experimental treatment and 
biomarker-negative patients receiving the control treatment and 𝑟𝐴−, 𝑟𝐵+ are the assumed response 
rates of biomarker-negative patients receiving the experimental treatment and biomarker-positive 
patients receiving the control treatment The prevalence of biomarker-positive patients corresponds 
to 𝑘. 
Statistical considerations: This design enables the evaluation of the interaction between the 
biomarker and different treatments and can estimate directly the marker-strategy response rate. 
Additionally, this subtype design allows the estimation of the effect size of the experimental 
treatment compared to the control treatment for each biomarker-defined subgroup separately. Also, 
there is no chance that the same treatment will be tailored to biomarker-positive patients who are 
randomized either to the biomarker-based strategy arm or the reverse marker strategy (i.e., 
biomarker-positive patients in the biomarker-based strategy will be given only the experimental 
treatment and biomarker-positive patients in the reverse marker strategy arm will be given only the 
control treatment). Also, there is no possibility of the same treatment assignment to biomarker-
negative patients who are randomly assigned to the two biomarker-based strategy arms (i.e., 
  
 
biomarker-negative patients in the marker-based strategy arm will be treated with the control 
treatment, whereas biomarker-negative patients in the reverse marker strategy arm will be treated 
with the experimental treatment). According to Eng, 2014 [92] who compared the reverse marker-
based strategy design with the first (i.e., biomarker-strategy design with biomarker assessment in the 
control arm) and third (i.e., biomarker-strategy design with treatment randomization in the control 
arm) subtype of biomarker-strategy designs in the case of binary outcomes, the effect size in order to 
make a comparison of the different treatment strategy arms would be larger than in the first and third 
subtype designs. Furthermore, it has been shown by Eng, 2014 that in situations where a randomly 
chosen treatment has a better than 7% response rate, the reverse marker-based strategy design works 
better as compared to the third biomarker-strategy subtype (i.e., Biomarker-strategy design with 
treatment randomization in the control arm). It has also been demonstrated that this novel design is 
more than four times more efficient in order to test the interaction between treatment and biomarker 
compared to Biomarker-strategy design with biomarker assessment in the control arm, Biomarker-
strategy design with randomization in the control arm and the marker stratified design. Eng, 2014 
demonstrated the benefits of the Reverse Marker-Based strategy design with the aim to assess the 
interaction between treatment and biomarker. However, Baker, 2014 [93] stated that other designs 
than the Reverse Marker-Based strategy design would be more appropriate in order to investigate 
questions which include treatment effect of biomarker-defined subgroups and biomarker-based 
strategy arms. 
2.5. Other Designs 
A Randomized Phase II Trial Design with Biomarker Proposed by Freidlin et al., 2012 
Freidlin et al., 2012 [71] proposed a biomarker-guided Phase II clinical trial design in which when 
it is completed, it recommends which type of Phase III trial should be used. These recommendations 
for a Phase III trial are the following: (i) enrichment design; (ii) marker-stratified design; (iii) a 
traditional trial design without a biomarker; or (iv) drop consideration of the experimental treatment. 
A graphical illustration of this design is given in Figure 16. 
 
Figure 16. Randomized Phase II trial design with biomarkers. “R” refers to randomization of patients. 
CI refers to the confidence interval. Uncolored boxes are referred to the first stage of the trial and 
colored boxes are referred to the second stage of the trial. 
  
 
Design: For this type of randomized Phase II trial, it is assumed that the experimental treatment 
will be more beneficial among biomarker-positive patients than biomarker-negative patients without 
ruling out the efficacy of the novel treatment in biomarker-negative patients. The intermediate 
endpoint of progression-free survival (PFS) is used which is able not only to give the results earlier 
but also to target larger treatment effects as compared to overall survival (OS) endpoint.  
The design starts by comparing the experimental treatment with the control treatment in the 
biomarker-positive subgroup using a one-sided level of significance 𝑎1 = 0.10. The null hypothesis 
is that the progression-free survival for biomarker-positive patients is the same for both experimental 
and control treatment arm (𝐻𝑅0,𝑏𝑖𝑜𝑚+ ≤ 1 vs. 𝐻𝑅1,𝑏𝑖𝑜𝑚+ > 1). Next, if the null hypothesis is rejected, 
which means that the experimental treatment is better than the control treatment in the biomarker-
positive subgroup we continue with the calculation of an 80% two-sided confidence interval (CI) for 
the hazard ratio (control vs experimental) in the biomarker-negative subpopulation. Three decisions 
are made according to the values of the CI: (i) if the entire CI is less than 1.3 then we can continue 
with a Phase III enrichment design; (ii) if the CI includes the values 1.3 or 1.5 then we can continue 
with a Phase III marker-stratified design and (iii) if the entire CI is greater than 1.5 then it seems that 
the biomarker is not useful as the novel treatment benefits only the biomarker-negative patients, thus, 
the biomarker should be dropped and a traditional randomized Phase III design should be 
conducted. Otherwise, if the null hypothesis is not rejected at the one-sided significance 𝑎1 = 0.10 
(meaning that that the experimental treatment is not better than the experimental treatment in the 
biomarker-positive subgroup), then we continue with the comparison of treatments in the overall 
study population at one-sided level of significance 𝑎 = 0.05. If the null hypothesis of no treatment 
effect in the entire population is rejected, then the authors recommend to drop the biomarker and to 
continue with a traditional randomized Phase III trial due to the fact that the biomarker seems to be 
useless. On the other hand, if the null hypothesis is not rejected, the experimental treatment should 
not be tested further as it does not seem to be effective.  
Utility: This design should be used when we want to conduct a Phase II randomized trial which 
allows decisions to be made about which type of Phase III biomarker-guided trial to proceed with. It 
is appropriate when there is prior evidence that the novel treatment benefits mostly the biomarker-
positive patients without ruling out treatment effect in biomarker-negative patients.  
Methodology: Freidlin et al., 2012 [71] have provided an online tool for calculating the sample 
size which can be found on the following website http://brb.nci.nih.gov/Data/FreidlinB/RP2BM [116]. 
In order for a sample size to be estimated, the following information is required: (i) the significance 
levels for testing the treatment effect in the biomarker-positive subgroup and in the entire population; 
(ii) cut-offs and confidence intervals for the hazard ratio in the biomarker-negative subgroup; (iii) the 
prevalence of biomarker-positive patients; (iv) the median progression-free survival in each 
treatment arm in each biomarker-defined subgroup and (v) the accrual parameters. Regarding the 
accrual parameters, the author specifies the minimum sample size for biomarker-positive patients for 
which the accrual continues until this number is reached, the maximum number of over-accrual in 
biomarker-positive subgroup for which the accrual to the entire population stops after this number 
is reached and the maximum accrual number in biomarker-negative patients for which the accrual to 
this biomarker-defined subgroup stops when this number is reached. 
Statistical considerations: In real life, it might not be possible to obtain the biomarker status for 
the entire population. If the biomarker status is unknown for some patients, then these individuals 
could be included in the analysis of the overall population. More precisely, in case that the 
proportions of patients with unknown biomarker status is low, the randomization of them to either 
the experimental or the control treatment could be considered in the second stage of this Phase II trial 
where we test the treatment effectiveness in the entire population. Another statistical consideration 
is that researchers should take into account the adjustment for inflation in Phase III type I error as the 
chosen Phase III trial design depends on the performance of the aforementioned randomized Phase 
II trial. Additionally, the authors suggest generally that in cases where it seems that the control 
treatment has been shown more beneficial, an aggressive interim inefficacy/futility should be used, 
i.e., when the estimated hazard ratio of control treatment versus the experimental treatment is equal 
  
 
or less than one when half of the required number of events have been observed, then the accrual 
should stop to that biomarker-defined subgroup. 
3. Discussion 
A number of biomarker-guided trial designs have been proposed in the past decade, including 
both biomarker-guided adaptive and non-adaptive trial designs. We have undertaken a 
comprehensive review of the literature using an in-depth search strategy to report on the biomarker-
guided designs proposed to date, with a view to providing the research community with clarity in 
definition, methodology and terminology of the various trial designs. The review is split in two parts 
due to its size; the first part of the review is focused on adaptive designs which are extensively 
discussed in our published paper “Biomarker-Guided Adaptive Trial Designs in Phase II and Phase 
III: a Methodological Review”, Antoniou et al., 2016 [35], whereas, herein we focus on non-adaptive 
designs which incorporate biomarkers.  
The review has demonstrated ambiguity and confusion regarding the biomarker-guided non-
adaptive designs proposed by different authors. In this review, we focus on 5 main types of such 
designs including their subtypes and variations. Knowledge on how to implement and analyse these 
designs are essential in testing the effectiveness of a biomarker-guided approach to treatment; hence, 
a comprehensive review giving this knowledge is essential for the research community. In our in-
depth study, we provide researchers with analytical information of these study designs not only in 
terms of their utility, advantages and limitations but also in terms of their methodology. In addition, 
a graphical illustration for each biomarker-guided design is given. A guidance document by Tajik et 
al., 2012 [117] regarding the evaluation of putative biomarkers in randomized clinical trials came to 
our knowledge by personal communication as we were not able to identify it during our literature 
search. 
The non-adaptive designs do not allow modifications of important aspects of the trial such as 
refinement of the existing study population, treatment assignment, study endpoints, study duration, 
etc. In non-adaptive designs, all these factors are defined before the initiation of the study and they 
are kept fixed during the course of the clinical trial. However, there is a great potential of failure when 
implementing such conventional designs due to potential wrong design assumptions of the key 
aspects of the study that might be made before the conduct of the trial. Hence, an adaptive design 
clinical study which allows on-going adaptations based on accumulating study data from interim 
analysis might hold advantageous position as compared to the non-adaptive trial design due to its 
flexibility. However, before implementing an adaptive design a lot of issues should be taken into 
careful consideration by research teams in order to prove that there are good reasons for conducting 
such designs. Regulatory and logistical issues, requirement of additional efforts for the achievement 
of the design, potential difficulties, possible increased cost and time, statistical challenges including 
the potential increase of the chance of a false conclusion that the treatment is effective (inflation of 
Type I error) and whether the adaptation process has led to positive study results that are difficult to 
interpret irrespective of having control of Type I error should be considered [130]. A recent paper by 
Dimairo et al., 2015 [131] refers to a number of obstacles and barriers when implementing adaptive 
designs in practice. Several key stakeholders in clinical trials research have been interviewed (i.e., UK 
Clinical Trials Units directors, funding board and panel members, statisticians, regulators, chief 
investigators, data monitoring committee members and health economists) expressing difficulties of 
adaptive designs. Lack of appropriate knowledge and familiarity of these designs in the scientific 
community, insufficient time and funding structure, additional work required due to the complexity 
of such designs and the needed statistical expertise and appropriate software are some of the 
highlighted difficulties mentioned in the paper of Dimairo et al., 2015 [131]. In addition, this study 
includes the characterisation of potential benefits of an adaptive design to patients, clinical trials as 
well as funders. 
The different designs proposed so far for biomarker-guided designs, both non-adaptive designs 
which remain an appealing approach to a great extent mainly due to their simplicity and adaptive 
designs which are more flexible need to be further explored by the research community, as the proper 
  
 
choice and use of such designs can result in a great increase in the efficiency of a trial and expedite 
the development of novel treatments. 
The characteristics and methodology of the five main designs and their subtypes are discussed 
in the current paper, whilst information on their variations are summarized in File S1-S4. Additional 
references for these variations and the literature review search strategy are provided in [132,133]. 
Supplementary Materials: The following are available online at www.mdpi.com/link, File S1-S4: Extensions of 
Biomarker-guided non-adaptive trial designs, Keywords S1: Literature review search strategies for both 
biomarker-guided clinical trial designs and for traditional trial designs. 
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